

# 1 Title

2 Rosetta FunFolDes – a general framework for the computational design of  
3 functional proteins

4

# 5 Authors

6

7 Jaume Bonet\*, Sarah Wehrle\*, Karen Schriever\*, Che Yang\*, Anne Billet, Fabian  
8 Sesterhenn, Andreas Scheck, Freyr Sverrisson, Sabrina Vollers, Roxanne  
9 Lourman, Melanie Villard, Stéphane Rosset, Bruno E. Correia.

10

11 \* These authors contributed equally to this work.

12

# 13 Affiliations

14 Institute of Bioengineering, École Polytechnique Fédérale de Lausanne,  
15 Lausanne, CH-1015, Switzerland

16 Swiss Institute of Bioinformatics (SIB), Lausanne, CH-1015, Switzerland

17

18

# 19 Abstract

20

21 The robust computational design of functional proteins has the potential to  
22 deeply impact translational research and broaden our understanding of the  
23 determinants of protein function, nevertheless, it remains a challenge for state-  
24 of-the-art methodologies. Here, we present a computational design approach  
25 that couples conformational folding with sequence design to embed functional  
26 motifs into heterologous proteins. We performed extensive benchmarks, where  
27 the most unexpected finding was that the design of function into proteins may  
28 not necessarily reside in the global minimum of the energetic landscape, which  
29 could have important implications in the field. We have computationally  
30 designed and experimentally characterized a distant structural template and a *de*  
31 *novo* “functionless” fold, two prototypical design challenges, to present

32 important viral epitopes. Overall, we present an accessible strategy to repurpose  
33 old protein folds for new functions, which may lead to important improvements  
34 on the computational design of functional proteins.

35

36

## 37 Introduction

38

39 Proteins are one of the main functional building blocks of the cell. The ability to  
40 create novel proteins outside of the natural realm has opened the path towards  
41 innovative achievements, such as new protein pathways (Cross et al., 2017),  
42 cellular functions (Joh et al., 2014), and therapeutic leads (Correia et al., 2010;  
43 Correia et al., 2014; Kulkarni et al., 2015). Computational protein design is the  
44 rational and structure-based approach to solve the inverse folding problem, i.e.  
45 the search for the best putative sequence capable of fitting and stabilizing a given  
46 protein's three-dimensional conformation (Coluzza, 2017). As such, a great deal  
47 of effort has been placed into the understanding of the rules of protein folding  
48 and stability (Koga et al., 2012; Marcos et al., 2017) and its relation to the  
49 appropriate sequence space (Kuhlman & Baker, 2000).

50

51 Computational protein design focus on two main axes of search related to the  
52 structural and sequence spaces that are explored. Fixed backbone approaches  
53 work with a static protein backbone conformation, which greatly constrains the  
54 sequence space that is explored by the computational algorithm (Kuhlman &  
55 Baker, 2000). Following the same principles as naturally occurring homologs,  
56 which often exhibit a certain degree of structural diversity, flexible backbone  
57 approaches enhance the sequence diversity, adding the challenge of identifying  
58 energetically favorable sequence variants that are correctly coupled to the  
59 structural perturbations (Murphy et al., 2012).

60

61 Another variation for computational design approaches is *de novo* design, in  
62 which protein backbones are assembled *in silico*, followed by sequence  
63 optimization to fold into a pre-defined three-dimensional conformation without  
64 being constrained by previous sequence information (Hill, Raleigh, Lombardi, &  
65 DeGrado, 2000). This approach tests our understanding of the rules governing  
66 the structure of different protein folds. The failures and successes of this  
67 approach confirm and correct the principles used for the protein design process  
68 (Koga et al., 2012; Marcos et al., 2017).

69

70 One of the main aims of computational protein design is the rational design of  
71 functional proteins capable of carrying existing or novel functions into new  
72 structural contexts (Street & Mayo, 1999). One can broadly classify three main  
73 approaches for the design of functional proteins: redesigning of pre-existing  
74 functions, grafting of functional sites onto heterologous proteins, and designing  
75 of novel functions not found in the protein repertoire. The redesign of a pre-  
76 existing function to alter its catalytic activity (Yu et al., 2014) or improve its  
77 binding target recognition (Guntas, Purbeck, & Kuhlman, 2010) can be  
78 considered the most conservative approach; as it is typically accomplished by  
79 point mutations around the functional area of interest, it tends to have little  
80 impact on global structure and stability of the designed protein. On the other  
81 hand, the design of fully novel functions has most noticeably been achieved by  
82 applying chemical principles that tested our fundamental knowledge of enzyme  
83 catalysis (Jiang et al., 2008; Kries, Blomberg, & Hilvert, 2013).

84

85 Between these two approaches resides protein grafting. This method aims to  
86 repurpose natural folds as carriers for exogenous known functions. It relies on  
87 the strong relationship between protein structure and activity, to allocate a given  
88 functionality from one protein to another by means of transferring the structural  
89 motif responsible for the function (Azoitei et al., 2011; Correia et al., 2011;  
90 Correia et al., 2010; Correia et al., 2014; Kulkarni et al., 2015; Procko et al., 2014;  
91 Viana et al., 2013). The most successful grafting approaches are highly  
92 dependent on structural similarity between the functional motif and the  
93 insertion region in the protein scaffold. When the functional motif and the  
94 insertion region are almost identical in backbone conformation, functional  
95 transfer can be performed by side-chain grafting, i.e. mutating the target  
96 residues into those of the functional motif (Correia et al., 2010; Kulkarni et al.,  
97 2015). In much more challenging scenarios, full backbone grafting may be used  
98 in conjunction with directed evolution to make the structure fully compatible  
99 with the new function (Azoitei et al., 2011). Nevertheless, motif transfer is  
100 limited between very similar structural regions, which greatly constrains the  
101 subset of putative scaffolds that can be used for this purpose, especially as the  
102 structural complexity of the functional motif grows.

103 Previously, we have demonstrated the possibility of expanding protein grafting  
104 to scaffolds with segments that have low structural similarity . To accomplish  
105 that task, we developed a prototype protocol named Rosetta Fold From Loops  
106 (FFL) (Correia et al., 2014; Procko et al., 2014).

107

108 The distinctive feature of our protocol is the coupling of the folding and design  
109 stages to bias the sampling towards structural conformations and sequences that  
110 stabilize the grafted functional motif. In the past, FFL was used to obtain designs  
111 that were functional (synthetic immunogens (Correia et al., 2014) and protein-  
112 based inhibitors (Procko et al., 2014)) and where the experimentally determined  
113 crystal structures closely resembled the computational models; however, the  
114 structures of the functional sites were still very close to the insertion segments  
115 of the hosting scaffolds.

116

117 Here, we present a complete re-implementation of the FFL protocol with  
118 enhanced functionalities, simplified user interface and complete integration with  
119 any other available Rosetta protocols. We have called this new, more generalist  
120 protocol Rosetta Functional Folding and Design (FunFolDes), we have  
121 benchmarked it in a number of scenarios providing important technical details  
122 to better exploit and expand the capabilities of the original protocol.  
123 Furthermore, we challenged FunFolDes with two design tasks to probe the  
124 boundaries of applicability of the protocol. The design tasks were centered on  
125 using distant structural template as hosting scaffold and functionalizing a *de*  
126 *novo* designed protein – in both challenges, FunFolDes succeeded in  
127 functionalizing the designed proteins. These results are encouraging and provide  
128 a solid basis for the broad applicability of FunFolDes as a strategy for the robust  
129 computational design of functionalized proteins.

130

131

## 132 Results

133

### 134 *Rosetta FunFoldes – a computational framework for design of functional* 135 *proteins*

136

137 The original prototype of the Rosetta Fold From Loops (FFL) protocol was  
138 successfully used to transplant the structural motif of the Respiratory Syncytial  
139 Virus (RSV) protein F site II neutralizing epitope into a protein scaffold in the  
140 context of a vaccine design application (Correia et al., 2014).

141 FFL enabled the insertion and conformational stabilization of the structural  
142 motif into a defined protein topology by using Rosetta's fragment insertion  
143 machinery to fold the polypeptide chain to adopt the desired topology (Rohl,  
144 Strauss, Misura, & Baker, 2004) which was then sequence designed. Information  
145 content from the scaffold structure was used to guide the folding, ensuring an  
146 overall similar topology while allowing for the conformational changes needed  
147 to stabilize the inserted structural motif.

148


149 The final implementation of the protocol, referred to as FunFoldes, is  
150 schematically represented in **Figure 1**, and fully described in Materials and  
151 Methods. Our upgrades to FFL focused on three main aims: I) improve the  
152 applicability of the system to allow handling of more complex structural motifs;  
153 II) enhance the design of functional proteins by including binding partners in the  
154 simulations; III) offer a higher degree of control over each stage of the simulation  
155 while improving the usability for non-experts. These three aims were achieved  
156 through the implementation of five core technical improvements described  
157 below.

158

159 *Insertion of multi-segment functional sites.* The initial implementation of FFL was  
160 limited to the insertion of a single-segment structural motif, which was sufficient  
161 to demonstrate its potential at the time (Correia et al., 2014; Procko et al., 2014).  
162 However, most functional sites in proteins typically entail, at the structural level,  
163 multiple discontinuous segments; which is the case for protein-protein interfaces  
164 or enzyme active-sites, among others (Aragues, Sali, Bonet, Marti-Renom, &

165 Oliva, 2007; Richter, Leaver-Fay, Khare, Bjelic, & Baker, 2011). FunFoldDes can  
166 now handle functional sites with any number of discontinuous segments,  
167 ensuring the native orientations of each of the segments. Furthermore, it allows  
168 control of the backbone flexibility of each of the insertion points and the order in  
169 the protein scaffold sequence in which each segment is inserted. Finally, the  
170 sequence length between the motif and the insertion region is not required to be  
171 the same, allowing the user to search for protein scaffolds using alternative  
172 metrics to the full backbone RMSDs between the motif and the protein scaffold  
173 (Azoitei et al., 2011; Correia et al., 2010). These new features essentially allow  
174 the replacement between completely different structural segments. Thus, they  
175 greatly enhance the types of structural motifs that can be targeted with  
176 FunFoldDes, widening the applicability of the computational protocol.

177



178

179 **Figure 1. Rosetta FunFolDes - method overview.** FunFolDes was devised to tackle a wide  
 180 range of functional protein design problems, combining a higher user control of the simulation  
 181 parameters whilst simultaneously lowering the level of expertise required. FunFolDes is able to  
 182 transfer single- and multi-segment motifs together with the target partner by exploiting Rosetta's  
 183 FoldTree framework (top row). A wider range of information can be extracted from the template  
 184 to shift the final conformation towards a more productive design space (middle row), including  
 185 targeted distance constraints, generation of structure-based fragments, motif insertion in sites  
 186 with different residue length and presence of the binding target to bias the folding stage. The  
 187 bottom row showcases the most typical application of the FunFolDes protocol. Integration in  
 188 RosettaScripts allows to tailor FunFolDes behavior and for a seamless integration with other



189 protocols, and complex selection logics can be added to address the different complexities in  
190 each design task.

191

192 *Structural folding and sequence design in the presence of a binding partner.* Many  
193 of the functional roles of proteins in cells require physical interaction with other  
194 proteins, nucleic acids, or metabolites (Garcia-Garcia et al., 2012). Several  
195 proposed mechanisms to regulate binding affinities and specificities in protein  
196 interactions involve protein flexibility, such as induced fit and conformational  
197 selection (Chakrabarti et al., 2016; Lange et al., 2008). Inspired by these  
198 naturally occurring mechanisms, we devised a strategy to fold and design in the  
199 presence of the desired binding partner. Including the binder in simulations has  
200 a twofold benefit. On the one hand, is a way of explicitly representing functional  
201 constraints to bias the designed protein towards a functional sequence space,  
202 resolving putative clashes derived from the template scaffold and, thus,  
203 significantly enlarging the number of usable templates. On the other hand, this  
204 approach facilitates the design of new additional contact residues (outside of the  
205 motif) that may afford enhanced affinity and/or specificity. Here, we tested  
206 FunFolDes in a model system for which extensive experimental data has been  
207 collected, and we show how this approach improves the sampling of productive  
208 conformational and sequence space.

209

210 *Region-specific structural constraints.* FFL could exploit distance constraints from  
211 the target scaffold to guide the folding stage. A simplified solution was  
212 implemented in FFL with two possible simulation modes, where either  
213 constraints are collected throughout the protein scaffold, or folding is  
214 unconstrained. Currently, FunFolDes can collect from full-template to region-  
215 specific constraints, allowing greater levels of flexibility in areas of the scaffold  
216 that can be critical for function (e.g. segments close to the interface of a target  
217 protein) and improving the sampling of conformations which otherwise could be  
218 missed or highly underrepresented. Furthermore, FunFolDes is no longer limited  
219 to atom-pair distance constraints (Rohl & Baker, 2002) and can incorporate  
220 other types of kinematic constraints, such as angle and dihedral constraints

221 (Bowers, Strauss, & Baker, 2000), which have been used to improve success  
222 rates when folding scaffolds rich in beta-strands (Marcos et al., 2017).

223

224 *On-the-fly fragment picking.* Fragment insertion is a core algorithm in Rosetta  
225 protocols exploring high degrees of freedom of the polypeptide chain, such as *ab*  
226 *initio* protein prediction (Simons, Ruczinski, et al., 1999), loop modeling (Stein &  
227 Kortemme, 2013), or more recently, FFL (Correia et al., 2014). Classically,  
228 fragment libraries are generated through sequence-based predictions of  
229 secondary structure and dihedral angles (Bowers et al., 2000). This information  
230 is used in a Rosetta application to obtain three- and nine residue-long fragment  
231 libraries from naturally occurring proteins, which are then provided to the  
232 downstream protocols. Leveraging internal functionalities in Rosetta, FunFolDes  
233 can assemble fragment sets automatically. Due to its particularities, secondary  
234 structure, dihedral angles, and accessible solvent area can be automatically  
235 computed from the protein scaffold's structure. Although sequence-based  
236 fragments can still be provided, this removes the need for secondary applications  
237 in the protocol pipeline, boosting the usability of FunFolDes by lowering the  
238 barrier for non-experts. It also enables the assembly of protocols in which the  
239 fragment sets are mutable along the procedure. The benchmark presented in this  
240 paper evaluates the performance of such functionality.

241

242 *Compatibility with other Rosetta modules.* Finally, FunFolDes is compatible with  
243 Rosetta's modular xml-interface: Rosetta Scripts (RS) (Fleishman et al., 2011).  
244 This enables customization of the FunFolDes protocol and, more importantly,  
245 connection with other protocols and filters available through the RS interface. In  
246 order to obtain a full integration with this interface, the FunFolDes protocol is  
247 divided in multiple *Movers* (i.e. modules capable of altering the information  
248 content of a structure).

249

250 We devised two benchmark scenarios to test the performance of FunFolDes. One  
251 of these aimed to capture conformational changes in small protein domains  
252 caused by sequence insertions or deletions, and the second scenario assessed

253 protocol performance to fold and design a binder in the presence of the target  
254 binding partner.

255

### 256 *Capturing conformational and sequence changes in small protein domains*


257

258 Typical protein design benchmarks are assembled by stripping native side  
259 chains from known protein structures and evaluating the sequence recovery of  
260 the design algorithm (Kuhlman & Baker, 2000). The main design aim of  
261 FunFoldDes is to insert structural motifs into protein folds while allowing  
262 flexibility across the overall structure. This conformational freedom allows the  
263 full protein scaffold to adapt and stabilize the functional motif's conformation.  
264 This is a main distinctive point from other approaches to design functional  
265 proteins that rely on a mostly rigid scaffold (Azoitei et al., 2011; Correia et al.,  
266 2010; Fallas et al., 2017; Hill et al., 2000; Joh et al., 2014; Richter et al., 2011). For  
267 many modeling problems, such as protein structure prediction, protein-protein  
268 and protein-ligand docking, or protein design, standardized benchmark datasets  
269 are available (Vreven et al., 2015) or easily accessible. Devising a benchmark for  
270 designed proteins with propagating conformational changes across the structure  
271 is challenging, as we are assessing both structural accuracy as well as sequence  
272 recovery of the protocol.

273

274 To address this problem, we analyzed structural domains found repeatedly in  
275 natural proteins and clustered them according to their definition in the CATH  
276 database (Dawson et al., 2017). As a result, we were able to select a set of 14  
277 benchmark targets labeled T01 through T14 (**Figure 2A**). A detailed description  
278 on the construction of the benchmark can be found in the Materials and Methods  
279 section.

280



281

282 **Figure 2. Benchmark test set to evaluate FunFolDes structural sampling.** A) Structural  
 283 representation of the 14 targets used in the benchmark. Each target highlights the motif (red),  
 284 the query region (blue), and the positions from which distance constraints were generated (light  
 285 blue). Conformations of the motif and query regions, as found in the template structures, appear  
 286 superimposed in a semi-transparent depiction. B) Full structure RMSD (Overall RMSD) and local  
 287 RMSD for the query region (FunFolDes - Query Region) for four targets (full dataset presented in  
 288 Supplementary Figure S1). Overall RMSD compares results for the two simulation modes  
 289 (FunFolDes Vs. constrained-*ab initio* (*cst-ab initio*)) and the two fragment generation methods  
 290 (structure-(blue) Vs. sequence-based fragments(green)). FunFolDes more frequently samples  
 291 RMSDs closer to the conformation of the target structure. Generally, structure-based fragment  
 292 also contribute to lower mean overall RMSDs. The FunFolDes - Query Region RMSD distributions  
 293 show that the two fragments sets do not have a major importance in the structural recovery of  
 294 the query region.

295

296 Briefly, for the benchmark we selected proteins with less than 100 residues,  
 297 where each benchmark test case is composed of two proteins of the same CATH  
 298 domain cluster. One of the proteins is dubbed template, and serves as a  
 299 structural representative of the CATH domain. The second protein, dubbed

300 target, contains structural insertions or deletions (motif), to which a structural  
301 change in a different segment of the same structure could be attributed (query  
302 region). The motif and query regions for all the targets are shown in **Figure 2A**  
303 and quantified in terms of the percentage of overall secondary structure in  
304 **Figure 2 - Supplementary Figure 1A**. To a great extent, these structural  
305 changes due to natural sequence insertions and deletions are analogous to those  
306 occurring in the design scenarios for which FunFolDes was conceived.

307

308 Using FunFolDes, we folded and designed the target proteins while maintaining  
309 the motif segment structurally fixed, mimicking a structural motif insertion.  
310 Distance constraints between residues were extracted from the template in the  
311 regions of shared structural elements of the template and the target, and were  
312 used to guide the folding simulations.

313


314 To check whether FunFolDes enhances sequence and structural sampling, we  
315 compared the simulations to constrained *ab initio* (*cst-ab initio*) simulations  
316 (Bowers et al., 2000). These simulations were performed using the same sets of  
317 constraints but without the motif region as a static segment.

318

319 As Rosetta conformational sampling is highly dependent upon the fragment set  
320 provided, in this benchmark we also tested the influence of structure- and  
321 sequence-based fragments. The performance of the two protocols was broadly  
322 analyzed by the global and local recovery of both structure and sequence.

323

324 Structural recovery was assessed through two main metrics: (a) global RMSD of  
325 the full decoys against the target and (b) local RMSD of the query region. When  
326 evaluating the distributions for global RMSD in the designed ensembles,  
327 FunFolDes outperformed *cst-ab initio* by consistently producing populations of  
328 decoys with lower mean (RMSDs mostly found below 5 Å), a result observed in  
329 all 14 targets (**Figure 2B, Figure 2 - Supplementary Figure 1B**). This result is  
330 especially reassuring considering that FFL simulations contain more structural  
331 information of the target topology than the *cst-ab initio* simulations.



333 **Figure 2 - Supplementary Figure 1. Structural composition and overall results of the**  
334 **benchmark targets.** A) Percentage of secondary structure type, motif and query region in the  
335 overall structures. B) Full structure RMSD (Overall RMSD) and local RMSD for the query region  
336 (Query Region) between the decoy populations and their respective targets. FunFoldDes tends to  
337 outperform *cst-ab initio* in all scenarios and the structure-based fragments yield decoy  
338 population with lower mean RMSDs, albeit with small differences relative to the sequence-based  
339 fragments.

340

341 Retrieval of the local RMSDs of the query unconstrained regions presented  
342 mixed results across the benchmark set. In 13 targets, FunFoldDes outperforms  
343 *cst-ab initio*, showing lower mean RMSDs in the decoy population.


344

345 When comparing fragment sets (structure- vs sequence-based), both achieved  
346 similar mean RMSDs in the decoy populations; nonetheless, the structure-based  
347 fragments more often reach the lowest RMSDs for overall and query RMSDs  
348 (**Figure 2B, Figure 2 – Supplementary Figure 1**). This is consistent with what  
349 would be expected of structural information content within each set of  
350 fragments. When paired with the technical simplicity of use, time-saving and  
351 enhanced sampling of the desired topology, the structure-based fragments are an  
352 added value for FunFoldDes.

353

354 In addition to structural metrics, we also quantified sequence recovery in the  
355 decoy populations, both in terms of sequence identity as well as sequence  
356 similarity according to the BLOSUM62 matrix (Henikoff & Henikoff, 1992)  
357 (**Figure 3A**). In all targets, the sequence identities and similarities were higher  
358 for FunFoldDes populations than for *cst-ab initio*, and in line with sequence  
359 recoveries presented for other design protocols (Murphy et al., 2012) (**Figure**  
360 **3A**). This type of metrics has been shown to be highly dependent on the exact  
361 backbone conformation used as input (Kuhlman & Baker, 2000; Murphy et al.,  
362 2012). Given that FunFoldDes is exploring larger conformational spaces, as a  
363 proxy for the quality of the sequences generated, we used the target's Hidden  
364 Markov Models (HMM) (Eddy, 2011) and quantified how many of the designed  
365 sequences were identified as belonging to the target's CATH superfamily  
366 according to its HMM definition (**Figure 3B**).

367



368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

**Figure 3. Assessment of FunFoldDes' sequence sampling quality of.** A) HMM Sequence Recovery measures the percentage of decoys generated that can be assigned to the original HMM from the CATH superfamily that the target belongs to. FunFoldDes consistently outperforms *cst-ab initio*, which is consistent with the same behavior observed in the structural recovery. B) Core Residues Sequence Recovery reveals the conservation of core residues between each design set and its target. Conservation is measured in terms of sequence identity and sequence similarity (as assigned through BLOSUM62). Also according to this metric FunFoldDes outperforms *cst-ab initio* in every instance, reaching, for some populations, levels of conservation similar to those found in more restrained flexible-backbone designs.

HMM recovery was computed as the percentage of decoys with an E-value under 10 and covering more than 50% of the full decoy sequence. FunFoldDes decoy populations systematically outperformed those from *cst-ab initio* (**Figure 3B**). The performance of the two fragment sets shows no significant differences. Core



383 sequence identity and similarity was assessed over the structure-based fragment  
384 set.

385

386 In summary, the results of this benchmark highlight the usability of FunFolDes to  
387 generate close-to-native scaffold proteins to stabilize inserted structural motifs.  
388 FunFolDes aims to refit protein scaffolds towards the requirements of a  
389 functional motif. In this perspective, it is critical to explore, within certain  
390 topological boundaries, structural variations around the original template. This  
391 benchmark points to several variables in the protocol that resulted in enhanced  
392 structural and sequence sampling.

393

#### 394 *Target-biased folding and design of protein binders*

395 The computational design of proteins that can bind with high affinity and  
396 specificity to targets of interest remains a largely unsolved problem (Schreiber &  
397 Fleishman, 2013). Within FunFolDes' conceptual approach of coupling folding  
398 with sequence design, we sought to add the structure of the binding target  
399 (**Figure 1**) to attempt to bias sampling towards functional structural and  
400 sequence spaces.


401

402 Previously, we used FFL to design a new binder (BINDI) to BHRF1 (**Figure 4A**),  
403 an Epstein-Barr virus protein with anti-apoptotic properties directly linked to  
404 the tumorigenic activity of EBV (Procko et al., 2014). FFL was used to generate  
405 the initial designs that bound to BHRF1 with a dissociation constant ( $K_D$ ) of 58-  
406 60 nM, which were then affinity matured ( $K_D = 220 \pm 50$  pM) and showed  
407 improved bacterial expression. BINDI was designed in the absence of the target  
408 and then docked to BHRF1 through the known interaction motif. The BHRF1-  
409 compatible models were further designed to ensure structural compatibility and  
410 improve affinity. A striking observation from the overall approach was that the  
411 FFL stage was highly inefficient, generating a large fraction of backbone  
412 conformations incompatible with the binding mode of the complex.

413

414

415



416

417 **Figure 4. Target-biased design of a protein binder and assessment of performance based**

418 **on saturation mutagenesis data.** A) Depiction of the initial design task, a single-segment

419 binding motif (BIM-BH3), shown in purple cartoon representation, with its target (BHRF1),

420 shown in gray surface is used by FunFolDes to generate an ensemble of designs compatible with

421 the binding mode. B) Conformational difference between the initial template (PDB ID: 3LHP) and

422 the previously designed binder (BINDI shown in pink cartoon representation), helix 3 requires a

423 subtle but necessary shift (2.6 Å) to avoid steric clashes with the target. C-G) Scoring metrics for

424 each design population according to the simulation mode: no\_target - FunFolDes was used

425 without the target protein; static - target present no flexibility allowed; pack - target allowed to

426 repack the side-chains; packmin - side-chain repacking plus minimization and backbone

427 minimization were allowed for the target. The target flexibility was allowed during the relax-

428 design cycle of FunFolDes. C) Structural drift observed for design and target binder measured as

429 the RMSD difference of each structure between pre- and post-minimization conformations. D)

430 Structural recovery of the conformation observed in the BINDI-BHRF1 assess over the 3 helical

431 segments of the bundle. E) Rosetta energy for the design populations generated with different

432 simulation modes. F) Interaction energy ( $\Delta\Delta G$ ) between the designs and the target. G) Deep-

433 sequence score distribution for each design population, computed as the mean score of each

434 sequence after applying a position score matrix based on the deep-sequence data. The pack  
435 population slightly outperforms the other simulation modes. H) Per-residue scoring comparison  
436 of the no\_target and the pack populations according to the deep-sequence data. Although the  
437 behavior is overall similar, pack outperforms no\_target in multiple positions, several of which are  
438 highlighted(black dots) as interfacial contacts or second shell residues close to the bind site  
439 which were allowed to be designed throughout the simulations.

440

441 To test whether the presence of the target could improve structural and  
442 sequence sampling, we leveraged the structural and sequence information  
443 available for the BINDI-BHRF1 and benchmarked FunFolDes for this design  
444 problem.

445


446 As described by Procko and colleagues, when comparing the topological  
447 template provided to FFL and the BINDI crystal structure, the last helix of the  
448 bundle (helix 3) was shifted relative to the template to ensure structural  
449 compatibility between BINDI and BHRF1 (**Figure 4B**). We used this case study to  
450 assess the capabilities of FunFolDes to sample closer conformations to those  
451 observed in the BINDI-BHRF1 crystal structure. In addition, we compared the  
452 saturation mutagenesis data generated for BINDI (Procko et al., 2014) to  
453 evaluate the sequence space sampled by FunFolDes.

454

455 A detailed description of this benchmark can be found in the Materials and  
456 Methods section. Briefly, we performed four different FunFolDes simulations: I)  
457 binding target absent (no\_target); II) binding target present with no  
458 conformational freedom (static); III) binding target present with side-chain  
459 repacking (pack); IV) binding target present with side-chain repacking plus  
460 minimization and backbone minimization (packmin). After the FunFolDes  
461 simulations, the no\_target set was docked to BHRF1 through the binding motif  
462 and the remaining three simulations produced complexed structures. All the  
463 complexes were globally minimized (both design and target) to assess the  
464 conformational and energy changes as a proxy of the structural compatibility of  
465 the designed binders.

466

467 Simulations performed with the target absent (no\_target) very rarely produce  
468 conformations compatible with the target (<10% of the total generated designs)  
469 (**Figure 4 - Supplementary Figure 1A**). We observed an improvement on the  
470 fraction of decoys compatible with the binding target (>60%) after global  
471 minimization (**Figure 4 - Supplementary Figure 1A**). However, this was at the  
472 cost of considerable structural drifts for both binder (mean RMSD 3.3 Å) and  
473 target (mean RMSD 7.7 Å) (**Figure 4C**). These structural drifts are a reflection of  
474 the energy optimization requirements by the relaxation algorithms but are  
475 deemed biologically irrelevant due to the profound structural reconfigurations.  
476 In contrast, simulations performed in the presence of the target clearly biased  
477 the sampling to more productive conformational spaces. RMSD drifts upon  
478 minimization were less than 1 Å for both designs and target (**Figure 4C**).  
479



480

481 **Figure 4 - Supplementary Figure 1. Target-biased folding and design: structural features**

482 **of the modeled designs and saturation mutagenesis data used for sequence recovery**

483 **benchmark.** A) Quantification of the percentage of decoys compatible with a design-target

484 binding conformation for the different simulation modes. The simulations performed without the

485 target yield a very low percentage of binding compatible conformations. After minimization, this

486 percentage increases with significant structural drifts. B) The initial template is a 3-helix bundle

487 structure, the slight shift needed to adopt a binding-compatible conformation produces only a

488 small global RMSD. C) Graphical representation of the deep-sequencing data as a position-

489 specific score matrix. Black borders highlight the native BINDI residue type for each position.

490 Mutations for which no data was obtained, likely reflect that these protein variants were unable

491 to fold and display at the surface of yeast and were assigned the lowest score of -5.

492

493 Given that global alignments of the designs do not emphasize the local  
494 differences and the helical arrangement (**Figure 4 - Supplementary Figure 1**),  
495 to analyze structural regions of particular interest, we aligned all the designs on  
496 the conserved binding motif (**Figure 4A**) and measured the RMSD over the three  
497 helices that compose the fold. The two key regions were helices 1 and 3, which  
498 are in direct contact with the target.

499

500 According to this metric, FunFoldes simulations in the presence of the target  
501 sampled mean RMSD of 3 Å with the BINDI structure as reference (**Figure 4D**),  
502 and the closest designs were at approximately 2 Å. On the other hand,  
503 simulations in the absence of the target showed a mean RMSD of 4.5 Å, and the  
504 best designs around 2.5 Å.

505 While we acknowledge that these structural differences are modest, the data in  
506 this benchmark suggest that these differences can be important in the sampling  
507 of conformations and sequences competent for binding.

508

509 In addition to structural sampling, we also analyzed Rosetta Energies for the  
510 different simulations. We observed noticeable differences in the overall energy  
511 of the designed binders; in the absence of the binding target, the designs have an  
512 mean energy of approximately -320 Rosetta Energy Units (REUs), while the  
513 designs generated in the presence of the binding target showed an mean  
514 between -280 and -290 REUs (**Figure 4E**). This difference is significant,  
515 particularly for a protein of such small size (116 residues). Likewise, we also  
516 observe considerable differences in terms of the binding energy ( $\Delta\Delta G$ ) for the  
517 designs folded in the absence or in the presence of the binding target,  
518 corresponding to mean  $\Delta\Delta G$ s of -10 and -50 REUs, respectively (**Figure 4E**).

519

520 The energy metrics provide interesting insights regarding the design of  
521 functional proteins. Although the sequence and structure optimization for the  
522 designs in the absence of the target reaches lower energies, these designs are  
523 structurally incompatible with the binding target and, even after refinement,  
524 their functional potential (as assessed by the  $\Delta\Delta G$ ) is not nearly as favorable as  
525 those performed in the presence of the binding target (**Figure 4F**). These data

526 suggest that, in many cases, to optimize function it may be necessary to sacrifice  
527 the overall computed energy of the protein which is often connected to the  
528 experimental thermodynamic stability of the protein. Although stability is an  
529 essential requirement for all functional proteins (Chevalier et al., 2017; Tokuriki,  
530 Stricher, Serrano, & Tawfik, 2008), it may be necessary to design proteins that  
531 are, *in silico*, less energetically favorable to ensure that the target functional  
532 requirements can be accommodated. This observation provides a compelling  
533 argument to perform biased simulations in the presence of the binding target,  
534 which may broadly be defined as a “functional constraint”.

535

536 To evaluate sequence sampling quality, we compared the computationally  
537 designed sequences to a saturation mutagenesis dataset available for BINDI  
538 (Procko et al., 2014). Briefly, this dataset was obtained by screening a saturation  
539 mutagenesis library for binding interactions in a yeast-display setup coupled to a  
540 deep sequencing readout. The impact on the binding affinity of each mutation  
541 was assessed based on the relative frequencies of the mutants. Data from this  
542 experiment were transformed into a positional scoring matrix (**Figure 4 –**  
543 **Supplementary Figure 1C**). Point mutations that showed a beneficial effect on  
544 the binding affinity to BHRF1 have a positive score, deleterious mutants a  
545 negative score, and neutral score 0. Such a scoring scheme, will yield a score of 0  
546 for the BINDI sequence.

547

548 When scoring the designs generated by the four different simulations, designs  
549 performed in the presence of the binding target obtain higher mean scores as  
550 compared to the no\_target designs (**Figure 4G**). The pack simulation, where the  
551 binding target is simply repacked, is the best performer with the highest  
552 distribution mean, having one design that scores better than the BINDI sequence.  
553 Furthermore, it is important to highlight that in some key positions at the  
554 protein-protein interface, the pack designs clearly outperformed those generated  
555 by the no\_target simulation, when quantified in terms of a per-position score  
556 (**Figure 4H**); meaning that across the design population, amino-acids that can be  
557 conducive to productive binding interactions were sampled more often in the  
558 presence of the binding target. This sequence sampling benchmark provides an

559 example of the benefits of using a “functional constraint” (binding target) to  
560 improve the quality of the sequences obtained by computational design.

561 Overall, the BINDI benchmark provides important insights regarding the best  
562 computational protocol within FunFoldes that can be utilized to improve the  
563 outcome of design simulations in terms of frequency of functional proteins.

564

### 565 ***Repurposing a naturally occurring fold for a new function***

566


567 At its conception, FFL was primarily envisioned to aid the design of function into  
568 proteins. To further test FunFoldes’ design capabilities, we sought to transplant  
569 a contiguous viral epitope that can be recognized by a monoclonal antibody with  
570 high affinity (**Figure 5A**). The success of the designs was assessed by their  
571 folding, thermal stability, and more importantly, binding affinities to the epitope-  
572 specific antibody as the functional readout.

573

574 Specifically, we used as functional motif the RSVF site II epitope (PDB ID: 3IXT  
575 (McLellan, Chen, Kim, et al., 2010)), a helix-loop-helix motif recognized by the  
576 antibody motavizumab (mota). Previously, we have designed proteins with this  
577 same epitope (Correia et al., 2014); however, we started from a structural  
578 template with a similar conformation to that of the epitope, the RMSD between  
579 the epitope and the scaffold segment was approximately 1 Å when measured  
580 over the helical positions. Here, we sought to challenge FunFoldes by using a  
581 distant structural template where the local RMSDs of the epitope structure and  
582 the segment onto which the epitope was transplanted would be over 2 Å. We  
583 used master (Zhou & Grigoryan, 2015) to perform a structural search of the site  
584 II epitope over a subset of structures in the PDB. After filtering the results by  
585 scaffold size (50-100 residues) and steric clashes using the structure of the  
586 epitope in complex with mota, we selected as template scaffold the structure of  
587 the A6 protein of the Antennal Chemosensory system from the moth *Mamestra*  
588 *brassicae* (PDB ID: 1KX8 (Lartigue et al., 2002))(**Figure 5A**). The backbone  
589 RMSD between the conformation of the epitope and the insertion region in 1kx8  
590 is 2.37 Å (**Figure 5B**).

591





592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

**Figure 5. Functional design of a distant structural template.** A) Structural representation of 1kx8. The insertion region is colored in light red and the two disulfide bonds are labeled (CYD). B) Structural comparison between the insertion region of 1kx8 and the mota epitope (light red-filled silhouette). Local RMSDs between the two segments reach 2.37 Å. C) Superimposition between 1kx8\_d2 design model (blue with red motif) and the 1kx8 template (wheat and light red insertion site). Multiple conformational shifts are required throughout the structure to accommodate the site II epitope. D) CD spectrum of 1kx8\_d2 showing a typical alpha-helical pattern with the ellipticity minimums at 208 nm and 220 nm. E) 1kx8\_d2 shows a melting temperature ( $T_m$ ) of 43.4°C. F) Binding affinity determined by SPR. 1kx8\_d2 shows a  $K_D$  of 1.14 nM. Experimental sensorgrams are shown in black and the fitted curves in red. G) Per-position evaluation of structural (top) and sequence (bottom) divergence between the design model 1kx8\_d2 and the starting template 1kx8. The largest structural differences are observed in the region where the site II epitope was inserted, the overall difference of the two structures is 2.25 Å (dashed line). Sequence divergence is evaluated by applying the BLOSUM62 score matrix to the sequences, yielding a total of 13.5% identity and 38.5% similarity mostly in the structured regions. The epitope region is colored in light red. Identical positions between the 1kx8\_d2 and 1kx8 are labeled with the residue one letter code while positively scored changes according to BLOSUM62 are labeled with a + symbol.


In terms of biological function, 1kx8 is involved in chemical communication and perception(Lartigue et al., 2002). Biochemically, it has been shown to bind to fatty-acid molecules with hydrophobic alkyl chains composed of 12-18 carbons.

615 Two prominent features are noticeable in the structure of 1kx8: two disulfide  
616 bonds (**Figure 5A**) and a considerable void volume in the protein core, deemed  
617 to be the binding site for fatty acid molecules. These features emphasize that the  
618 initial design template is likely not a very stable protein.

619

620 In the design process we performed two stages of FunFoldEs simulations; first  
621 an exploratory stage to select properly folded designs with the functional motif  
622 inserted (**Figure 5C**) that were fed into a second round of simulations, which  
623 sampled much more extensively within the structural proximity of the 1<sup>st</sup>  
624 generation template. For each stage, we generated 12'500 designs, eventually  
625 selecting seven for initial experimental characterization according to several  
626 structural features of the computational models, namely: Rosetta Energy,  
627 packing score, and buried unsatisfied hydrogen bonds (**Figure 5 -**  
628 **Supplementary Figure 1**). A detailed description of the process can be found in  
629 the Materials and Methods.

630




631

632 **Figure 5 - Supplementary Figure 1. Structural and sequence evaluation of the**  
633 **computational designs.** Assessment of structural and sequence features: Rosetta Energy,  
634 packing score (packstat) (Alford et al., 2017), cavity volume, Buried UNSatisfied polar atoms and  
635 secondary structure prediction (PSIPRED) for the template and the computational designs. Each  
636 template (green diamond) and design (yellow and blue circles) are compared against a set of  
637 non-redundant minimized structures of similar size ( $\pm 15$  residues). A) Due to its natural  
638 function, 1kx8 presents of a large cavity to bind its hydrophobic ligands. As such, the structure  
639 presents generally low scores as compared to computationally designed proteins. B)  
640 Distributions of the structural and sequence features of natural proteins and the TOP7 series of  
641 designs.

642

643 We characterized experimentally the computationally designed; those expressed  
644 in bacteria at good yields were further characterized using size exclusion  
645 chromatography coupled to a multi-angle light scatter (SEC-MALS) to determine  
646 the solution oligomerization state. To assess their folding and thermal  
647 stability( $T_m$ ) we used Circular Dichroism (CD) spectroscopy, and finally to assess  
648 their functional properties we used surface plasmon resonance (SPR) to  
649 determine binding dissociation constants ( $K_{DS}$ ) to the mota antibody. We started  
650 by expressing seven sequences from our first round of computational design; out  
651 of these seven, six designs were purified and characterized further. While the  
652 majority of the designs were monomers in solution and showed CD spectra  
653 typical of helical proteins, in terms of stability we obtained both designs that  
654 were not very stable nor did they exhibit cooperative unfolding (1kx8\_02) and  
655 also designs that were very stable and did not fully unfold under high  
656 temperatures (1kx8\_07) (**Figure 5 – Supplementary Figure 2**).

657



658

659

**Figure 5 - Supplementary Figure 2. Examples of experimental characterization performed for other variants on the 1kx8 design series.** A) CD wavelength spectra (left column), thermal denaturations (middle column) and SPR binding assays with the mota antibody (right column) were performed. B) Global sequence alignment of the wild-type protein 1kx8 and the computationally designed sequences. Red positions highlight the site II epitope insertion. Green positions highlight the cysteines performing the disulfide bridges. The two positions that consistently kept the original residue type of 1kx8 are highlighted in bold.

666

667

The determined binding affinities to mota ranged from 34 to 208 nM, which was an encouraging result. Nevertheless, comparing this affinity range to those of the peptide epitope ( $K_D = 20$  nM) and other designs with the same site grafted that were published previously ( $K_D = 20$  pM) (Correia et al., 2014), there was room for improvement. Therefore, we generated a second round of designs to attempt to improve stability and binding affinities. Driven by the observation that the

672

673 native fold has two disulfides bonds, our next set of designs included engineered  
674 disulfide bonds.

675

676 In the second round, we tested eight designed variants with different disulfide  
677 bonds and, if necessary, additional mutations to accommodate them. All eight  
678 designs were soluble after purification and two were monomeric: 1kx8\_d2 and  
679 1kx8\_3\_d1, which also showed CD spectra typical of helical proteins (**Figure 5D**)  
680 with melting temperatures ( $T_m$ s) of 43 and 48°C (**Figure 5E**), respectively.  
681 Remarkably, 1kx8\_d2 showed a  $K_D$  of 1.14 nM (**Figure 5F**), an improvement of  
682 approximately 30-fold compared to the best variants of the first round. 1kx8\_d2  
683 binds to the mota with approximately 20-fold higher affinity than the peptide-  
684 epitope ( $K_D \approx 20$  nM), and 50 fold lower compared to previously designed  
685 synthetic scaffolds ( $K_D = 20$  pM) (Correia et al., 2014). This difference in binding  
686 is likely reflective of how challenging it can be to accomplish the repurposing of  
687 protein structures with distant structural similarity.

688

689 Post-design analyses were performed to compare the sequence and structure of  
690 the best design model with the initial template. **Figure 5G**, shows a per-residue  
691 RMSD measurement upon a global alignment of the 1kx8 structure with the  
692 designed model. The global RMSD between the two structures is 2.25 Å. Much of  
693 the structural variability arises from the inserted motif, while the surrounding  
694 segments adopt a configuration similar to the original template scaffold. The  
695 sequence identity of 1kx8\_d2 as compared to the native protein is approximately  
696 13%. The sequence conservation per-position (**Figure 5G**) was evaluated  
697 through the BLOSUM62 matrix, where positive scores are attributed if the  
698 original residue is not mutated or if the substitution is deemed favorable  
699 according the scoring matrix, and negative if unfavorable. Overall, 38.5% of the  
700 residues in 1kx8\_d2 scored positively, and 61.4% of the residues had a score  
701 equal to or lower than 0. This is particularly interesting in the perspective that  
702 multiple mutations deemed unfavorable according the statistics condensed in  
703 the BLOSUM62 matrix are still able to yield well folded and, in this case,  
704 functional proteins.

705

706 The successful design of this protein is a relevant demonstration of both the  
707 broad usability of the FFL algorithm and of the overall strategy of designing  
708 functional proteins by coupling the folding and design process to incorporate  
709 functional motifs in unrelated protein folds. In a subsequent design challenge, we  
710 sought to functionalize a *de novo* design fold, which unlike natural proteins, did  
711 not evolve under any sort of functional pressure.


712

### 713 ***Functionalization of a functionless fold***

714

715 Advances in computational design methodologies have achieved remarkable  
716 results in the design of *de novo* protein sequences and structures (Hill et al.,  
717 2000; Koga et al., 2012; Marcos et al., 2017). However, the majority of the  
718 designed proteins are “functionless” and were designed to test the performance  
719 of computational algorithms in predicting structural accuracy. Here, we sought  
720 to use one of the hallmark proteins of *de novo* design efforts – TOP7 (Kuhlman et  
721 al., 2003) (**Figure 6A**) – and functionalize it using FunFolDes. To do so, we  
722 leveraged several of the newly implemented features in FunFolDes. The  
723 functional site selected to insert into TOP7 was another viral epitope from RSVF,  
724 commonly referred to as site IV, which is recognized by the 101F antibody  
725 (McLellan, Chen, Chang, et al., 2010). When bound to the 101F antibody, site IV  
726 adopts a  $\beta$ -strand-like conformation (**Figure 6B**), which in terms of secondary  
727 structure content is compatible with one of the edge strands of the TOP7  
728 topology (**Figure 6C**). Despite the secondary structure similarity, the RMSD of  
729 the site IV backbone in comparison with that of TOP7 is 2.1 Å, and upon  
730 alignment of the antibody in this particular orientation, clashes arise between  
731 TOP7’s helix 1 and the antibody interface. Therefore, this design challenge is yet  
732 another prototypical application for FunFolDes. In this design challenge we  
733 followed two distinct routes: I) a conservative approach where we fixed the  
734 amino-acid identities of roughly half of the core of TOP7 and allowed mutations  
735 mostly on the contacting shell of the epitope insertion site; and II) a sequence  
736 unconstrained design where all the positions of the scaffold were allowed to  
737 mutate. We attempted five designs for recombinant expression in *E. coli* and two  
738 (TOP7\_full and TOP7\_partial) were selected for further biochemical and

739 biophysical characterization, one from each of the two design strategies  
 740 mentioned above. According to SEC-MALS, both behaved as monomers in  
 741 solution, with TOP7\_partial being a less well-behaved protein with higher  
 742 aggregation propensity. Both TOP7\_full and TOP7\_partial (**Supplementary Figure 5**)  
 743 were folded according to CD measurements, with the TOP7\_full showing a CD  
 744 spectrum (**Figure 6D**) which very closely resembles that of the native TOP7  
 745 (Kuhlman et al., 2003). TOP7\_full was subjected to thermal denaturation  
 746 monitored by CD, where we observed that the newly designed protein is much  
 747 less stable than the original TOP7 (**Figure 6E**). To quantify the functional  
 748 component of TOP7\_full, we determined the  $K_D$  of its interaction with 101F to be  
 749 24.2 nM (**Figure 6F**), which is within the range measured for the native viral  
 750 protein RSVF (3.6 nM) (McLellan, Chen, Chang, et al., 2010). Importantly, the  $K_D$   
 751 for TOP7\_full is 2400 fold higher than that of the peptide-epitope (58.4  $\mu$ M)  
 752 (McLellan, Chen, Chang, et al., 2010), suggesting that productive conformational  
 753 stabilization and/or extra contacts to the rest of the protein were successfully  
 754 designed.  
 755



756

757 **Figure 6. Functionalization of the functionless de novo fold TOP7.** A) Structure of TOP7 with  
 758 the insertion region highlighted in light red. B) Structural comparison between 101F and the  
 759 insertion region of TOP7 reveals a 2.07 Å RMSD. C) TOP7\_full model (in blue and red for the

760 motif) superimposed over the TOP7 crystal structure. 101F's insertion is structurally  
761 compensated mostly by the first pairing beta strand and a shift of the first alpha helix D) CD  
762 spectrum shows a broad ellipticity signal between 210 nm and 222 nm as a representative of  
763 mixed secondary structural propensities. E) The melting temperature ( $T_m$ ) for TOP7\_full was  
764 54.5 °C. F) Binding affinity determined by SPR. TOP7\_full shows a  $K_D$  of 24.2 nM. Experimental  
765 sensorgrams are shown in black and the fitted curves in red. G) Per-position evaluation of  
766 structural (top) and sequence (bottom) divergence between the design model TOP7\_full and the  
767 starting template TOP7. The largest structural differences are observed in the region  
768 downstream of the site IV epitope, the overall difference of the two structures is 1.5 Å (dashed  
769 line). Sequence divergence is evaluated by applying the BLOSUM62 score matrix to the  
770 sequences, yielding a total of 27.7% identity and 52.2% similarity. The epitope region is colored  
771 in light red. Identical positions between the TOP7\_full and TOP7 are displayed as their residue  
772 types while positively scored changes according to BLOSUM62 are labeled with a + symbol.

773


774 Given the successful functionalization of TOP7, we sought to understand the  
775 levels of sequence and structural change (**Figure 6G**). Per-residue sequence  
776 recovery and structural similarity were evaluated for TOP7\_full against TOP7  
777 (**Figure 6G**). We compared the per-residue RMSD between the TOP7\_full model  
778 and the crystal structure of TOP7, revealing that most conformational changes  
779 occur from the site IV insertion region and displacement of the neighboring  
780 alpha-helix, with the overall backbone RMSD between both structures being 1.5  
781 Å. The connecting loop between the strand that holds the epitope and the  
782 adjacent strand was also shortened to obtain a tighter connection between the 2  
783 strands (**Figure 6C**).

784

785 Remarkably, the sequence identity of the most aggressive design (TOP7\_full) is  
786 only 28%, and using the BLOSUM62 based scoring system, we observe that most  
787 of the TOP7\_full residues were actually favorable, obtaining positive scores. This  
788 low conservation is especially relevant considering that intensive studies on  
789 TOP7 have revealed the importance of beta-sheet conservation in order to keep  
790 its foldability (Boschek et al., 2009; Soares, Boschek, Apiyo, Baird, & Straatsma,  
791 2010; Viana et al., 2013).

792





793

794

**Figure 6 - Supplementary Figure 1. Experimental characterization of TOP7\_variants.** A)

795

Experimental characterization for the TOP7\_partial design: SEC-MALS elution profile (left

796

column); CD wavelength scan spectrum; SPR binding assays with the 101F antibody (right

797

column). Noticeably the TOP7\_partia show a CD spectrum notoriously different from WT TOP7

798

and the TOP7\_full design. B) Global sequence alignment of the wild-type protein TOP7 and the

799

computationally designed sequences. Red positions highlight the site IV epitope insertion.

800

801 In summary, our results show that FunFoldes was able to repurpose a

802 functionless protein by folding and designing its structure to harbor a functional

803 site, which in this case was a viral epitope. Previously, these computationally

804 designed proteins with embedded viral epitopes were dubbed epitope-scaffolds

805 and showed their biomedical applicability as immunogens that were able to elicit

806 viral neutralizing antibodies(Correia et al., 2014).

807

808

## 809 Discussion and Conclusions

810

811 The robust computational design of proteins that bear a biochemical function  
812 remains an important challenge for present methodologies. The ability to  
813 consistently repurpose old folds for new functions or the *de novo* design of  
814 functional proteins could bring new insights into the determinants necessary to  
815 encode function into proteins (e.g. dynamics, stability, etc.) as well as important  
816 advances in translational applications (e.g. biotechnology, biomedical,  
817 biomaterials, etc.).

818 Here, we present the second-generation computational design protocol Rosetta  
819 FunFoldes, which was conceived to embed functional motifs into protein  
820 topologies, allowing for a global retrofitting of the overall protein topology to  
821 favorably host the functional motif. FunFoldes has evolved to incorporate two  
822 types of constraints to guide the design process: topological and functional. The  
823 former entail the fragments to assemble the protein structure and sets of  
824 distance constraints that bias the folding trajectories towards a desired topology;  
825 and the latter are the structure of the functional motif inserted and the binding  
826 target, if used.

827

828 We have extensively benchmarked the protocol, leveraging natural structural  
829 and sequence variation of proteins within the same fold, as well as deep  
830 mutational scanning data for the computationally designed protein BINDI. In our  
831 first benchmark, we observed that with FunFoldes we can efficiently bias the  
832 sampling towards improved structural and sequence spaces. Protocol features  
833 that enable higher quality sampling in design simulations are extremely  
834 important. Improved sampling may contribute to solving some of the major  
835 limitations in protein design, related to “junk” sampling, where most of the  
836 generated designs are not physically realistic, exhibiting obvious flaws according  
837 to general principles of protein structure. Importantly, higher quality sampling  
838 will likely contribute to improve the success rate of designs that are tested  
839 experimentally. The BINDI benchmark allowed us to test FunFoldes in a system  
840 with a large amount of experimental data, which included both sequences and  
841 structures. Perhaps the most enlightening observation was that designs that

842 were theoretically within a sequence/structure space productive for binding to  
843 the target were rather far from the energetic minimum that the protein fold can  
844 achieve in the absence of the binding target. Considering that the large majority  
845 of the design algorithms are energy “greedy” and the sequence/structure  
846 searches are performed with the central objective of finding the global minimum  
847 of the energetic landscape, by introducing functional constrains into the  
848 simulations, FunFolDes presents an alternative way of designing functional  
849 molecules and efficiently skewing the searches towards off-minima regions of  
850 the global landscape. We anticipate that such finding will be more relevant for  
851 protein scaffolds that need to undergo a large degree of structural adaptation to  
852 perform the desired function. If confirmed that this finding is generalized across  
853 multiple design problems, it could be an important contribution for the field of  
854 computational protein design.

855

856 Furthermore, we used FunFolDes to tackle two design challenges and  
857 functionalized two proteins with two distinct viral epitopes. These design  
858 challenges were devised to test the applicability of FunFolDes. Importantly, in  
859 previous applications FFL always used three-helix bundles as design templates,  
860 here we diversified the template folds and used an all-helical protein that is not a  
861 bundle (1kx8) and a mixed alpha-beta protein (TOP7), clearly showing the  
862 applicability to other folds. For the 1kx8 design series, we evaluated the  
863 capability of using distant structural templates as starting topologies as a  
864 demonstration of how one can use the many naturally occurring protein  
865 structures available and repurpose their function even when the initial template  
866 and the target structures are quite different. We obtained stable proteins that  
867 were recognized by an anti-RSV antibody with high affinity, showing that in this  
868 case, we successfully repurposed a distant structural template for a different  
869 function, a task for which other computational approaches (Silva, Correia, &  
870 Procko, 2016) would have limited applicability. We see this result as an exciting  
871 step forward towards using the wealth of the natural structural repertoire for  
872 the design of novel functional proteins.

873

874 In a last effort, we functionalized a “functionless” fold, based on one of the first *de*  
875 *novo* designed proteins – TOP7. For us, this challenge has important implications  
876 in order to understand the design determinants and biochemical consequences  
877 of inserting a functional motif into a protein that was mainly optimized for  
878 thermodynamic stability. We were successful in functionalizing TOP7 differently  
879 than previous published efforts, where TOP7 was mostly used as a carrier  
880 protein with functional motifs fused onto loop regions or side chains grafted in  
881 the helical regions, while our functional motif was embedded in the beta sheet of  
882 the protein template (Boschek et al., 2009; Soares et al., 2010; Viana et al., 2013).  
883 Exciting advances in the area of *de novo* protein design are also yielding many  
884 new proteins, which could then be functionalized with FunFolDes, highlighting  
885 the usefulness of this approach. Interestingly, we observed that the  
886 functionalized version of TOP7 showed a dramatic decrease in thermodynamic  
887 stability as compared to the parent protein. While this observation can be the  
888 result of many different factors, it is compelling to interpret it as the “price of  
889 function”, meaning that to harbor function, the TOP7 protein was penalized in  
890 terms of stability, which would be consistent with our findings in the BINDI  
891 benchmark example.

892 Recently, there have also been several *de novo* proteins which were designed for  
893 functional purposes (Chevalier et al., 2017); however, these efforts were limited  
894 to linear motifs that carried the functions, and the functionalization was mainly  
895 accomplished by side-chain grafting (Correia et al., 2010; Kulkarni et al., 2015)  
896 and relied on screening of a much larger number of designed proteins.

897

898 From our perspective, and considering all the technical improvements,  
899 FunFolDes has matured to become a valuable resource for the robust  
900 functionalization of proteins using computational design. Here, we present a  
901 number of important findings provided by the detailed benchmarks performed  
902 and used the protocol to functionalize proteins in design tasks which are  
903 representative of some of the common challenges that the broad scientific  
904 community faces when using computational design approaches.

905

## 906 Materials and Methods

907

### 908 *Computational protocol description*

909

910 Rosetta Functional Folding and Design (FunFolDes) is a general approach for  
911 grafting functional motifs into protein scaffolds. It's main purpose is to provide  
912 an accessible tool to tackle specifically those cases in which structural similarity  
913 between the functional motif and the insertion region is low, thus expanding the  
914 pool of structural templates that can be considered useful scaffolds. This  
915 objective is achieved by folding the scaffold after motif insertion while keeping  
916 the structural motif static. This process allows the scaffold's conformation to  
917 change and properly adapt to the three dimensional restrictions enforced by the  
918 functional motif. The pipeline of the protocol (summarized in **Figure 1**) proceeds  
919 as follows:

920

921 I) *Selection of the functional motif*. A single or multi-segment motif must be  
922 selected and provided as an input. In the most common mode of the protocol  
923 dihedral angles, side chain identities and conformations are kept fixed  
924 throughout the whole protocol.

925

926 II) *Selection of the protein scaffold*. Searches for starting protein scaffolds can be  
927 achieved, but are not limited to, RMSD similarity matches to the Protein Data  
928 Bank (PDB) (Rose et al., 2017). The ability of FunFolDes to adapt the scaffold to  
929 the needs of the motif widens the structural space of what can be considered as a  
930 suitable template. Thus, this step requires human intervention and has to be  
931 performed outside of the main protocol.

932

933 III) *Generation of fragment databases*. The usage of fragments lies at the core of  
934 many Rosetta protocols, particularly those that perform large explorations of the  
935 conformational space required for structure prediction and design. The most  
936 standard way of assembling fragment sets is to generate sequence-based  
937 fragments using the FragmentPicker application (Kim, Blum, Bradley, & Baker,  
938 2009). Despite the usefulness of the sequence-based fragments in typical design

939 and structure prediction problems, FunFoldDes-derived designs depend on the  
940 structural content of the template rather than its sequence. Thus we  
941 implemented the *StructFragmentMover*, a mover that performs on-the-fly  
942 fragment picking based on secondary structure, dihedral angles and solvent  
943 accessibility, calculated from the template's structural information. The typical  
944 three- and nine residue-long fragment sets are generated from the fragment  
945 database included in the Rosetta tools release.

946

947 IV) *Generation of constraints*. Residue-pair distance and backbone dihedral angle  
948 constraints can be extracted from the protein scaffold to guide the folding  
949 process. These constraints may include the full-length protein or focus in specific  
950 segments while allowing a wider flexibility in other regions. Although not  
951 required, the use of constraints greatly increases the quality of the sampling. The  
952 protocol can be also made aware of other constraint types (such as cartesian  
953 constraints) by properly modifying the score functions applied to the *ab initio*  
954 stage (Simons, Bonneau, Ruczinski, & Baker, 1999).

955

956 V) *Construction of the extended pose*. The extended structure is composed of all  
957 the segments of the target motif maintain their native backbone conformation  
958 and internal rigid body orientation. The scaffold residues are linearly attached to  
959 previously defined insertion points. In multi-segment motif scenarios, the  
960 construct will present a chain break between each of the motif composing  
961 segments. The number of chain-breaks in the pose scales with the number of  
962 segments( $n$ ) within a motif always resulting in  $n-1$  chain-breaks. Once the  
963 extended pose is assembled, it is represented at the centroid level (all side-chain  
964 atoms in a single virtual atom) to reduce the computational cost of the  
965 simulation.

966

967 VI) *Folding the extended pose*. Fragment insertion is performed to accomplish the  
968 folding stage. Kinematics of the pose are controlled through the FoldTree (Wang,  
969 Bradley, & Baker, 2007), a system to control the propagation of the torsion  
970 angles applied to a structure. In single-segment motif structures, the FoldTree  
971 starts in the center of the motif and propagates in opposite directions towards

972 the N- and C-terminal of the protein. In multi-segment motifs, in which the pose  
973 bears chain-breaks between each pair of motif segments, the FoldTree has a  
974 fixed node in the center of each segment and expands towards both sides  
975 (**Figure 1**). The chain-breaks in the structure are marked as cut-points, which  
976 avoid further propagation of the kinematic movement throughout the  
977 polypeptide chain, and are subjected to a score term to promote their spatial  
978 proximity. All the nodes of the FoldTree are placed in the motif segments are  
979 kept fixed relative to each other in three-dimensional space; this setup allows for  
980 the folding of the protein while maintaining the relative position of all the motif  
981 segments.

982

983 VII) *Inclusion of the binding target*. If a binding target (protein, nucleic acid or  
984 small molecule ligand) is provided, a new FoldTree node is added to the closest  
985 residue between the first motif segment and each binding element. Similarly to  
986 the multi-segment kinematics, this ensures that the rigid-body orientation  
987 between the motif and its target is maintained. FunFoldes can handle  
988 simulations with both multi-segment and binding targets simultaneously.

989

990 VIII) *Folding post-processing*. Folding trajectories are considered successful if  
991 they generate structures under a user-defined RMSD threshold of the starting  
992 scaffold. In case of a multi-segment motif, a preliminary loop closure will be  
993 executed to generate a continuous polypeptide chain, and the kinematic setup  
994 maintained to avoid segment displacement during the design step. After the  
995 folding stage performed at the centroid level, full atom information is recovered.  
996 All the steps necessary to perform the setup of the extended pose (kinematic  
997 setup, folding, post-processing) are carried out by a newly implemented mover  
998 called *NubInitioMover*.

999

1000 IX) *Protein design and conformational relaxation*. The folded structure is  
1001 subjected to iterative cycles of sequence design (Hu, Wang, Ke, & Kuhlman,  
1002 2007) and structural relaxation (Tyka et al., 2011) in which the sequence search  
1003 is coupled with confined conformational sampling (Kuhlman & Baker, 2004). A  
1004 MoveMap is defined to control backbone dihedrals and side chain conformations

1005 of the motif segments and the binding target while allowing for backbone and  
1006 side-chain exploration of the movable residues. TaskOperations are used to  
1007 avoid undesired mutations in the functional motif.

1008

1009 X) *Loop closure*. If multi-segment motifs are used, a final loop closure step is  
1010 required in order to obtain a polypeptide chain without breaks. The  
1011 *NubInitioLoopClosureMover* performs this last step using the Cyclic Coordinate  
1012 Descend (CCD) protocol (Wang et al., 2007), while ensuring that the original  
1013 conformation and rigid-body orientation of the motifs is maintained. After the  
1014 closure of each cut-point, a final round of fixed backbone design is performed on  
1015 the residues of the cut-points and surroundings.

1016

1017 XI) *Selection, scoring and ranking*. Finally, the decoys are ranked and selected  
1018 according to Rosetta energy, structural metrics (core packing, buried unsatisfied  
1019 polar atoms, etc) (Alford et al., 2017), sequence-based predictions such as  
1020 secondary structure propensity (Jones, 1999) and folding propensity (Simons,  
1021 Bonneau, et al., 1999) or any other metrics accessible through RosettaScripts  
1022 (RS).

1023

1024 The pipeline components described here represent the most standardized  
1025 version of the FunFoldes protocol. By means of its integration in RS, different  
1026 stages can be added, removed or modified to tailor the protocol to the specific  
1027 needs of the design problem at hand.

1028

1029 *Capturing conformational and sequence changes in small protein domains*

1030

1031 To test the ability of FunFoldes to recover the required conformational changes  
1032 to stabilize a given structural motif, we created a benchmark of 14 target cases of  
1033 proteins with less than 100 residues, named T01 to T14. Each target case was  
1034 composed of two structures of the same CATH superfamily (Dawson et al., 2017).  
1035 One of the structures was representative of the shared structural features of the  
1036 CATH family; we called this structure the reference. The second protein within  
1037 each target case presents two structural variations with respect to the reference:



1038 I) an insertion or deletion (indel) region and II) a conformational change. Direct  
 1039 structural contacts between these two regions make it so that the indel region is  
 1040 the cause for the conformational change. We called this second structure the  
 1041 target (**Figure 2, Table 1**).

1042

1043

ID	CATH	#	reference	target	motif range
<b>T01</b>	CATH.3.40.140.10	1	1pgxA	2pw9C	69-73
<b>T02</b>	CATH.3.30.310.50	1	3i3wA	4bjua	464-486
<b>T03</b>	CATH.3.30.70.980	1	1lfpA	1mw7A	140-150
<b>T04</b>	CATH.3.30.70.100	1	1rjjA	1lq9A	19-45
<b>T05</b>	CATH.3.10.20.30	1	2q5wD	2pkoA	49-64
<b>T06</b>	CATH.2.30.29.30	1	1c1yB	1h4rA	39-59
<b>T07</b>	CATH.3.10.20.90	1	2bkfA	2al6B	115-119
<b>T08</b>	CATH.3.10.20.90	1	1wj4a	1wiaA	181-200
<b>T09</b>	CATH.3.10.20.90	1	3ny5B	3phxB	100-121
<b>T10</b>	CATH.3.10.20.310	1	2x8xX	2qdfA	103-121
<b>T11</b>	CATH.3.10.320.10	1	4p5mA	2bc4C	56-66
<b>T12</b>	CATH.2.40.40.20	1	1cr5B	2pjhB	119-142
<b>T13</b>	CATH.2.40.40.20	2	1cr5B	2pjhB	119-142, 168-173
<b>T14</b>	CATH.3.30.110.40	1	1jdqA	3lvjC	14-37

1044 **Table 1. Targets included in the conformational and sequence recovery benchmark.** For  
 1045 each of the benchmark target is indicated the CATH superfamily and representatives used in the  
 1046 simulations. (#) indicates the number of segments in the target protein that are considered motif.  
 1047 Motif range indicates the residues considered motif according to the PDB numbering.

1048

1049 For each template protein we generated approximately 10000 decoys with  
 1050 FunFoldes by folding the target with the following conditions: 1) the indel region  
 1051 was considered as the motif, meaning that its structural conformation was kept  
 1052 fixed and no mutations allowed; 2) residue-pair distance constraints were  
 1053 derived from the secondary structure elements conserved between reference  
 1054 and the target (constrained region); 3) the region of the protein which showed

1055 the largest structural variations (query region) was constraint-free throughout  
1056 the simulation.

1057

1058 FunFolDes simulations were compared with constrained *ab initio* (*cst-ab initio*)  
1059 simulations, the key difference between them being that the *cst-ab initio*  
1060 simulations allowed for backbone flexibility in the motif region. The comparison  
1061 between both approaches provides insights on the effects of a static segment in  
1062 the folding trajectory of the polypeptide chain. In both scenarios a threshold was  
1063 set after the folding stage where only decoys that had less than 5 Å RMSD from  
1064 the template were carried to the design stage.

1065

1066 The importance of the input fragments was assessed with our benchmark. Both  
1067 protocols were tested with sequence-based fragments and structure-based  
1068 fragments generated on-the-fly by FunFolDes. Comparison between the two  
1069 types of fragments provides insight into how to utilize FunFolDes in the most  
1070 productive manner.

1071

1072 Structural recovery was evaluated by RMSD with the target structure. Global  
1073 RMSD, understood as the minimum possible RMSD given the most optimal  
1074 structural alignment, was used to assess the overall structural recovery of each  
1075 decoy population. Local RMSD, was evaluated for the unconstrained (query)  
1076 region and the motif by aligning each decoy to the template through the  
1077 constrained segments (excluding the motif). This metric aimed to capture the  
1078 specific conformational changes required to accommodate the motif into the  
1079 structure (**Figure 2B, Figure 2 - Supplementary Figure S1B**).

1080

1081 Sequence recovery was evaluated through two different criteria, sequence  
1082 associated statistics and Hidden Markov Model (HMM) (Eddy, 2011). For the  
1083 sequence associated statistics, we quantified sequence identity and similarity  
1084 according to BLOSUM62 for the core residues of each protein, as defined by  
1085 Rosetta's *LayerSelector* (Koga et al., 2012). Motif residues, that were not allowed  
1086 to mutate, were excluded from the statistics. In the second criteria, position  
1087 specific scoring matrices with inter-position dependency known as Hidden

1088 Markov Model (HMM) were used to evaluate fold specific sequence signatures. In  
1089 this case, the closest HMM to the template structure provided by CATH was used  
1090 to query the decoys and identify those that matched the HMM under two  
1091 conditions: I) an e-value under 10 and II) a sequence coverage over 50%.  
1092 Although these conditions are wide, they were within the variability found  
1093 between members of CATH superfamilies with high structural and sequence  
1094 variability like the ones used in the benchmark.

1095

#### 1096 *Target-biased design of protein binders*

1097

1098 To assess the performance of FunFoldes in the presence of a binder target we  
1099 recreated the design of BINDI as a binder for BHRF1 (Procko et al., 2014), the  
1100 BHRF1 binding motif from the BIM BH3 protein (PDB ID:2WH6 (Kvansakul et al.,  
1101 2010)) was inserted into a previously described 3-helix bundle scaffold (PDB  
1102 ID:3LHP (Correia et al., 2010)).

1103

1104 On that account, four different design simulations were performed: one without  
1105 the binder (no\_target) and three in the presence of the binder (static, pack and  
1106 packmin). The difference between the last three relates to how the binding target  
1107 was handled. In the static simulations the binding target was kept fixed and no  
1108 conformational movement in the side chains was allowed throughout the  
1109 protocol. In the pack simulations the side chains of the binding target were  
1110 repacked during the binder design stage. Finally, in the packmin simulations the  
1111 binding target side-chains were allowed to repack and both side-chains and  
1112 backbone were subjected to minimization. These three target configurations are  
1113 easily obtained by altering MoveMap definitions, demonstrating the flexibility of  
1114 the protocol to include variable conditions. In all cases, the two terminal residues  
1115 on each termini of the binding motif were allowed backbone movement to  
1116 optimize the insertion in the 3-helix bundle scaffold. For each one of these  
1117 scenarios, approximately 20000 decoys were generated.

1118

1119 For the no\_target simulations the FunFoldes designs were docked to BHRF1  
1120 using the inserted motif as guide to assess their complementary and interface

1121 metrics. In all the simulations, a final round of global minimization was  
1122 performed where both proteins of the complex were allowed backbone  
1123 flexibility. During this minimization, the jump between the design and target was  
1124 kept fixed to maintain the binding motif and target in place. The final  $\Delta\Delta G$  of the  
1125 complexes was measured after the minimization step to enable comparasions  
1126 between the no\_target decoys and the remaining simulation modes. Structural  
1127 changes related to this minimization step were evaluated as the global RMSD  
1128 between each structure before and after the process, this measure is referred to  
1129 as RMSD drift.

1130

1131 Structural evaluation includes global RMSD against the BINDI design crystal  
1132 structure (PDB ID: 4OYD (Procko et al., 2014)) as well as local RMSD against  
1133 regions of interest of BINDI. For the Local-RMSD the structures were aligned  
1134 through the inserted motif, as it was kept throughout all simulations and with  
1135 respect to BINDI. The local RMSD analysis was performed over all the helical  
1136 segments contained in the structures (all H), which provides a measurement of  
1137 the structural shifts on the secondary structure regions of the designs.

1138

1139 To evaluate the sequence recovery of our simulations we leveraged BINDI's  
1140 saturation mutagenesis data analyzed by deep sequencing performed in the by  
1141 Procko et al (Procko et al., 2014). The experimental fitness of each mutation was  
1142 summarized in a score matrix where a score was assigned for each amino-acid  
1143 substitution for the 116 positions of the protein (**Figure 4 – Supplementary**  
1144 **Figure 1**). In summary, point mutations that improved BINDI's binding to  
1145 BHRF1 are assigned positive scores while deleterious mutations present  
1146 negative values. These scores are computed based on experimental data where  
1147 the relative populations of each mutant were compared between a positive  
1148 population of cells displaying the designs (binders) and negative populations  
1149 (mutants that display but don't bind), these experiments have been described in  
1150 detail elsewhere(Procko et al., 2014). After normalization by the score of the  
1151 final BINDI sequence in each position, a position sequence specific matrix  
1152 (PSSM) was created. Like the original data, this matrix also assigns a positive  
1153 score to each point mutation if it resulted in an improved binding for the design.

1154 This normalization provides a score of 0 for the BINDI sequence, which is useful  
1155 as a reference score.

1156

1157 *Repurposing naturally occurring folds for a new functions*

1158

1159 To experimentally validate the capabilities of FunFoldes and insert functional  
1160 sites in structurally distant templates, we decided to transfer the site II epitope  
1161 from the Respiratory Syncytial Virus (RSV) protein F (PDB ID:3IXT (McLellan,  
1162 Chen, Kim, et al., 2010)) into heterologous scaffolds. This is a continuous, single  
1163 segment, helix-loop-helix conformation epitope. The main objective was to  
1164 challenge the capabilities of FunFoldes to reshape the structure of the scaffold to  
1165 the requirements of the functional motif, we aimed to search for insertion  
1166 segments with RMSDs towards the site II structure higher than 2 Å.

1167

1168 We searched for host scaffolds using MASTER (Zhou & Grigoryan, 2015) where  
1169 we used the full-length site II segment as a query against a subset of 17539  
1170 protein structures from the PDB composed of 30% non-redundant sequences  
1171 included in the MASTER distribution. The RMSD between the query and  
1172 segments on the scaffolds were assessed using backbone  $C_{\alpha}$ s. All matches with  
1173  $RMSD_{C_{\alpha}} < 5.5$  Å relative to site II were recovered and further filtered by protein  
1174 size, where only proteins between 50 and 100 residues were kept. These  
1175 scaffolds were then ranked regarding antibody-binding compatibility, where  
1176 each match was realigned to the antibody-epitope complex and steric clashes  
1177 between all glycine versions of the scaffold and antibody were quantified using  
1178 Rosetta. All matching scaffolds with  $\Delta\Delta G$  values above 100 REU were discarded  
1179 under the assumption that their compatibility with the antibody binding mode  
1180 was to low. The remaining scaffolds were visually inspected and PDB ID: 1kx8  
1181 (Lartigue et al., 2002) ( $RMSD_{C_{\alpha}} = 2.37$  Å) was selected for design with FunFoldes.

1182

1183 The twenty-one residues from the site II epitope (motif) as present in 3IXT were  
1184 grafted into a same sized segment (residues 79-100) of 1kx8 using the  
1185 *NubInitioMover*. Up to three residues in each insertion region of the motif were  
1186 allowed backbone flexibility in order to allow proper conformational transitions

1187 in the insertion points . Atom pair constraints with a standard deviation of 3 Å  
1188 were defined for all template residues, leaving the motif residues free of  
1189 constraints. The generous standard deviation was set up to favour necessary  
1190 conformational changes to allow the optimal fitting of the motif within the  
1191 topology . Regardless, the total allowed deviation for template was limited at 5 Å  
1192 to ensure the retrieval of the same topology. In this design series we used  
1193 sequence-based fragments generated with the 1kx8 native sequence. Three  
1194 cycles of design/relax were performed on the template residues with the  
1195 *FastDesignMover*.

1196

1197 A first generation of 12500 designs was ranked according to Rosetta energy.  
1198 From the top 50 decoys, only one presented the motif without distortions on the  
1199 edges derived from the allowed terminal flexibility. This decoy was used as  
1200 template on the second generation of FunFolDes to enhance the sampling of  
1201 properly folded conformations, with the same input conditions as the previous  
1202 one.

1203

1204 In the second generation, the top 50 decoys according to Rosetta energy were  
1205 further optimized through additional cycles of design/relax. After a selection  
1206 based on Rosetta energy, buried unsatisfied polars and secondary structure  
1207 prediction using PSIPRED (Jones, 1999), a total of 7 designs were manually  
1208 optimized and selected for experimental characterization. After the initial  
1209 characterization, designs with added disulphide bridges were generated in order  
1210 to improve protein stability and affinity (**Figure 4 – Supplementary Figures 1**  
1211 **and 2**).

1212

1213 *Functionalization of a functionless fold*

1214

1215 In a second effort to test the design capabilities of FunFolDes we sought to insert  
1216 a functional motif in one of the first de novo designed proteins – TOP7 (PDB ID:  
1217 1QYS) (Kuhlman et al., Science, 2003).

1218

1219 Six residues from the complex between the antibody 101F and the peptide-  
1220 epitope, corresponding to residues 429-434 (RGIKT) on the full-length RSV F  
1221 protein (McLellan, Chen, Chang, et al., 2010), were grafted into the edge strand of  
1222 the TOP7 backbone using FunFolDes. The choice between epitope and hosting  
1223 scaffold was made based on the secondary structure adopted by the epitope and  
1224 the acceptable structural compatibility of the TOP7 structure, the  $RMSD_{C\alpha}$   
1225 between the epitope and the insertion segment was 2.07 Å.

1226

1227 To ensure that the majority of the  $\beta$ -strand secondary structure was maintained  
1228 throughout the grafting protocol, the epitope motif was extended by one residue  
1229 and a designed 4-residue  $\beta$ -strand (KVTV) pairing with the backbone of the C-  
1230 terminal epitope residues was co-grafted as a discontinuous segment into the  
1231 adjacent strand in the TOP7 backbone. With this strategy we circumvented a  
1232 Rosetta sampling limitation, where often times is necessary an extensive set of  
1233 constraints to achieve the desired backbone hydrogen-bond pairing on beta-  
1234 strands (Marcos et al., 2017). After defining the motif consisting of the epitope  
1235 plus the pairing strand and the sites of insertion on the TOP7 scaffold, FunFolDes  
1236 was used to graft the motif.

1237

1238 Backbone flexibility was allowed for the terminal residues of the functional motif  
1239 and a  $\beta$ -turn connection between the two strands was modelled during the  
1240 folding process (*NubInitioMover*). During the folding process, 101F antibody was  
1241 added to the simulation in order to limit the explored conformational space  
1242 towards binding productive designs. Finally, the *NubInitioLoopClosureMover* was  
1243 applied to ensure that a proper polypeptide chain was modelled and no chain-  
1244 breaks remained, a total of 800 centroid models were generated after this stage.  
1245 Next, we applied an RMSD filter to select scaffolds with similar topology to TOP7  
1246 ( $< 1.5$  Å) and a hydrogen bond long-range backbone score (HB\_LR term) to  
1247 favour the selection of proteins with proper beta-sheet pairing. The top 100  
1248 models according the HB\_LR score and that also fulfilled the RMSD filter, were  
1249 then subjected to an iterative sequence-design relax protocol, alternating fixed  
1250 backbone side-chain design and backbone relaxation using the *FastDesignMover*.  
1251 Designable positions were limited to a subset of residues according to their

1252 position in the core or surface of the protein and secondary structure identity.  
1253 Two different design strategies were pursued: I) partial design - amino acid  
1254 identities of the C-terminal half of the protein (residues 45 through 92) were  
1255 retained from TOP7 while allowing repacking of the side chains and backbone  
1256 relaxation; II) full-design - the full sequence space in all residues of the structure  
1257 (with the exception of the 101F epitope) was explored. No backbone or side  
1258 chain movements were allowed in the 6-residue epitope segment whereas the  
1259 adjacently paired  $\beta$ -strand was allowed to both mutate and relax. Tight  $C\alpha$  atom-  
1260 pair distance constraints (standard deviation of 0.5 Å) were used to restrain  
1261 movements of the entire sheet throughout the structural relaxation iterations.

1262

1263 From the 100 designs generated, only those that passed a structural filter  
1264 requiring that 80% of secondary structure composition of the  $\beta$ -sheet after  
1265 backbone relaxation were selected for further analysis. The 93 designs passing  
1266 this filter were evaluated based on several metrics such as: REU, hydrogen-bond  
1267 long-range backbone interactions and core packing. The best-scored designs  
1268 were finally submitted to human-guided optimisation, mutations of single  
1269 surface residues (1-3) and shortening of the connecting loop between the two  
1270 inserted strands using the Rosetta Remodel application.

1271

1272 Interestingly, in an attempt to reproduce the same grafting exercise with  
1273 *MotifGraftMover* (Silva et al., 2016), this resulted in non-resolvable chain breaks  
1274 when trying to graft either the two segment-motif or the epitope alone into the  
1275 TOP7 scaffold.

1276

### 1277 *Protein Expression and Purification*

1278

1279 DNA sequences of the designs were purchased from Twist Bioscience. For  
1280 bacterial expression the DNA fragments were cloned via Gibson cloning into a  
1281 pET21b vector containing a C-terminal His-tag and transformed into *E. coli*  
1282 BL21(DE3). Expression was conducted in Terrific Broth supplemented with  
1283 ampicillin (100  $\mu$ g/ml). Cultures were inoculated at an  $OD_{600}$  of 0.1 from an  
1284 overnight culture and incubated at 37°C with a shaking speed of 220 rpm. After  
1285 reaching  $OD_{600}$  of 0.7, expression was induced by the addition of 1 mM IPTG and



1286 cells were further incubated for 4-5h at 37°C. Cells were harvested by  
1287 centrifugation and pellets were resuspended in lysis buffer (50 mM TRIS, pH 7.5,  
1288 500 mM NaCl, 5% Glycerol, 1 mg/ml lysozyme, 1 mM PMSF, 1 µg/ml DNase).  
1289 Resuspended cells were sonicated and clarified by centrifugation. Ni-NTA  
1290 purification of sterile-filtered (0.22 µm) supernatant was performed using a 1 ml  
1291 His-Trap™ FF column on an ÄKTA pure system (GE healthcare). Bound proteins  
1292 were eluted using an imidazole concentration of 300 mM. Concentrated proteins  
1293 were further purified by size exclusion chromatography on a Superdex™ 75  
1294 300/10 or a Superdex™ Hiload 16/600 75 µg column (GE Healthcare) using PBS  
1295 buffer (pH 7.4) as mobile phase.

1296 For IgG expression, heavy and light chain DNA sequences were cloned separately  
1297 into pFUSE-CHIg-hG1 (InvivoGen) mammalian expression vectors. Expression  
1298 plasmids were co-transfected into HEK293-F cells in FreeStyle™ medium  
1299 (Gibco™) using polyethylenimine (Polysciences) transfection. Supernatants  
1300 were harvested after 1 week by centrifugation and purified using a 5 ml  
1301 HiTrap™ Protein A HP column (GE Healthcare). Elution of bound proteins was  
1302 accomplished using a 0.1 M glycine buffer (pH 2.7) and eluents were  
1303 immediately neutralized by the addition of 1 M TRIS ethylamine (pH 9). The  
1304 eluted IgGs were further purified by size exclusion chromatography on a  
1305 Superdex 200 10/300 GL column (GE Healthcare) in PBS buffer (pH 7.4). Protein  
1306 concentrations were determined by measuring the absorbance at 280 nm using  
1307 the sequence calculated extinction coefficient on a Nanodrop (Thermo  
1308 Scientific).

1309

### 1310 *Circular Dichroism (CD)*

1311

1312 Far-UV circular dichroism spectra of designed scaffolds were collected between a  
1313 wavelength of 190 nm to 250 nm on a Jasco J-815 CD spectrometer in a 1 mm  
1314 path-length quartz cuvette. Proteins were dissolved in PBS buffer (pH 7.4) at  
1315 concentrations between 20 µM and 40 µM. Wavelength spectra were averaged  
1316 from two scans with a scanning speed of 20 nm min<sup>-1</sup> and a response time of  
1317 0.125 sec. The thermal denaturation curves were collected by measuring the  
1318 change in ellipticity at 220 nm from 20 to 95°C with 2 or 5 °C increments.

1319

1320 *Size-exclusion Chromatography combined with Multi-Angle Light-Scattering (SEC-*  
1321 *MALS)*

1322

1323 Multi-angle light scattering was used to assess the monodispersity and molecular  
1324 weight of the proteins. Samples containing between 50 -100 µg of protein in PBS  
1325 buffer (pH 7.4) were injected into a Superdex™ 75 300/10 GL column (GE  
1326 Healthcare) using an HPLC system (Ultimate 3000, Thermo Scientific) at a flow  
1327 rate of 0.5 ml min<sup>-1</sup> coupled in-line to a multi-angle light scattering device  
1328 (miniDAWN TREOS, Wyatt). Static light-scattering signal was recorded from  
1329 three different scattering angles. The scatter data were analysed by ASTRA  
1330 software (version 6.1, Wyatt)

1331

1332 *Surface Plasmon Resonance (SPR)*

1333

1334 To determine the dissociation constants of the designs to the mota or 101F  
1335 antibody, surface plasmon resonance was used. Experiments were performed on  
1336 a Biacore 8K at room temperature with HBS-EP+ running buffer (10 mM HEPES  
1337 pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005% v/v Surfactant P20) (GE Healthcare).  
1338 Approximately 1200 response units of mota or 101F antibody were immobilized  
1339 via amine coupling on the methylcarboxyl dextran surface of a CM5 chip (GE  
1340 Healthcare). Varying protein concentrations were injected over the surface at a  
1341 flow rate of 30 µl/min with a contact time of 120 sec and a following dissociation  
1342 period of 400 sec. Following each injection cycle, ligand regeneration was  
1343 performed using 3M MgCl<sub>2</sub> (GE Healthcare). Data analysis was performed using  
1344 1:1 Langmuir binding kinetic fits within the Biacore evaluation software (GE  
1345 Healthcare).

1346

1347 *Availability*

1348

1349 FunFoldes is available as part of the Rosetta software suite and is fully  
1350 documented in the Rosetta Commons documentation website as one of the  
1351 Composite Protocols. All data and scripts necessary to recreate the analysis and

1352 design simulations described in this work are available at  
1353 <https://github.com/lpdi-epfl/FunFolDesData>.

1354

#### 1355 *Contributions*

1356

1357 J.B. coded the algorithm described. A.S coded the *StructFragMover*. K.S., A.B., A.S.  
1358 and F.S. performed computational design simulations. S.W., K.S, C.Y., A.B., F.S.,  
1359 S.V., R. L., M. V. and S.R. contributed to experimental characterization of the  
1360 designed proteins. J.B. and B.E.C. designed the study and wrote manuscript.

1361

#### 1362 *Acknowledgements*

1363 We would like to acknowledge the High performance computing facility (SCITAS)  
1364 for their technical support. We would also like to acknowledge the Swiss  
1365 National Supercomputing Centre (CSCS) for their support in computing time. We  
1366 would like to thank the protein expression and characterization platform  
1367 (PCRYCF/PECF) for their support with mammalian expression and access to  
1368 analytical instrumentation. We would like to thank Erik Procko for providing the  
1369 data for the saturation mutagenesis on BINDI.

1370

#### 1371 *Funding*

1372

1373 B.E.C. is a grantee from the European Research Council (Starting grant - 716058),  
1374 the Swiss National Science Foundation (310030\_163139), Biltema Foundation.  
1375 This work was also supported by the Swiss National Science Foundation as part  
1376 of the NCCR Molecular Systems Engineering (51NF40-141825). J.B. is sponsored  
1377 by an EPFL-Fellows grant funded by an H2020 Marie Skłodowska-Curie action.  
1378 F.S. is funded by the Swiss Systemsx.ch initiative for systems biology.

1379

#### 1380 *References*

1381

1382 Alford, R. F., Leaver-Fay, A., Jeliazkov, J. R., O'Meara, M. J., DiMaio, F. P., Park, H., . . .  
1383 . Gray, J. J. (2017). The Rosetta All-Atom Energy Function for  
1384 Macromolecular Modeling and Design. *J Chem Theory Comput*, 13(6),  
1385 3031-3048. doi:10.1021/acs.jctc.7b00125

- 1386 Aragues, R., Sali, A., Bonet, J., Marti-Renom, M. A., & Oliva, B. (2007).  
1387 Characterization of protein hubs by inferring interacting motifs from  
1388 protein interactions. *PLoS Comput Biol*, 3(9), 1761-1771.  
1389 doi:10.1371/journal.pcbi.0030178
- 1390 Azoitei, M. L., Correia, B. E., Ban, Y. E., Carrico, C., Kalyuzhniy, O., Chen, L., . . .  
1391 Schief, W. R. (2011). Computation-guided backbone grafting of a  
1392 discontinuous motif onto a protein scaffold. *Science*, 334(6054), 373-376.  
1393 doi:10.1126/science.1209368
- 1394 Boschek, C. B., Apiyo, D. O., Soares, T. A., Engelmann, H. E., Pefaur, N. B.,  
1395 Straatsma, T. P., & Baird, C. L. (2009). Engineering an ultra-stable affinity  
1396 reagent based on Top7. *Protein Engineering Design & Selection*, 22(5),  
1397 325-332. doi:10.1093/protein/gzp007
- 1398 Bowers, P. M., Strauss, C. E., & Baker, D. (2000). De novo protein structure  
1399 determination using sparse NMR data. *J Biomol NMR*, 18(4), 311-318.
- 1400 Chakrabarti, K. S., Agafonov, R. V., Pontiggia, F., Otten, R., Higgins, M. K., Schertler,  
1401 G. F. X., . . . Kern, D. (2016). Conformational Selection in a Protein-Protein  
1402 Interaction Revealed by Dynamic Pathway Analysis. *Cell Rep*, 14(1), 32-  
1403 42. doi:10.1016/j.celrep.2015.12.010
- 1404 Chevalier, A., Silva, D. A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., . . .  
1405 Baker, D. (2017). Massively parallel de novo protein design for targeted  
1406 therapeutics. *Nature*, 550(7674), 74-79. doi:10.1038/nature23912
- 1407 Coluzza, I. (2017). Computational protein design: a review. *J Phys Condens  
1408 Matter*, 29(14), 143001. doi:10.1088/1361-648X/aa5c76
- 1409 Correia, B. E., Ban, Y. E., Friend, D. J., Ellingson, K., Xu, H., Boni, E., . . . Schief, W. R.  
1410 (2011). Computational protein design using flexible backbone remodeling  
1411 and resurfacing: case studies in structure-based antigen design. *J Mol Biol*,  
1412 405(1), 284-297. doi:10.1016/j.jmb.2010.09.061
- 1413 Correia, B. E., Ban, Y. E., Holmes, M. A., Xu, H., Ellingson, K., Kraft, Z., . . . Schief, W.  
1414 R. (2010). Computational design of epitope-scaffolds allows induction of  
1415 antibodies specific for a poorly immunogenic HIV vaccine epitope.  
1416 *Structure*, 18(9), 1116-1126. doi:10.1016/j.str.2010.06.010
- 1417 Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., . . .  
1418 Schief, W. R. (2014). Proof of principle for epitope-focused vaccine design.  
1419 *Nature*, 507(7491), 201-206. doi:10.1038/nature12966
- 1420 Cross, L. L., Paudyal, R., Kamisugi, Y., Berry, A., Cuming, A. C., Baker, A., &  
1421 Warriner, S. L. (2017). Towards designer organelles by subverting the  
1422 peroxisomal import pathway. *Nat Commun*, 8(1), 454.  
1423 doi:10.1038/s41467-017-00487-7
- 1424 Dawson, N. L., Lewis, T. E., Das, S., Lees, J. G., Lee, D., Ashford, P., . . . Sillitoe, I.  
1425 (2017). CATH: an expanded resource to predict protein function through  
1426 structure and sequence. *Nucleic Acids Res*, 45(D1), D289-D295.  
1427 doi:10.1093/nar/gkw1098
- 1428 Eddy, S. R. (2011). Accelerated Profile HMM Searches. *PLoS Comput Biol*, 7(10),  
1429 e1002195. doi:10.1371/journal.pcbi.1002195
- 1430 Fallas, J. A., Ueda, G., Sheffler, W., Nguyen, V., McNamara, D. E., Sankaran, B., . . .  
1431 Baker, D. (2017). Computational design of self-assembling cyclic protein  
1432 homo-oligomers. *Nat Chem*, 9(4), 353-360. doi:10.1038/nchem.2673
- 1433 Fleishman, S. J., Leaver-Fay, A., Corn, J. E., Strauch, E. M., Khare, S. D., Koga, N., . . .  
1434 Baker, D. (2011). RosettaScripts: a scripting language interface to the

- 1435 Rosetta macromolecular modeling suite. *PLoS One*, 6(6), e20161.  
1436 doi:10.1371/journal.pone.0020161
- 1437 Garcia-Garcia, J., Bonet, J., Guney, E., Fornes, O., Planas, J., & Oliva, B. (2012).  
1438 Networks of Protein-Protein Interactions: From Uncertainty to Molecular  
1439 Details. *Mol Inform*, 31(5), 342-362. doi:10.1002/minf.201200005
- 1440 Guntas, G., Purbeck, C., & Kuhlman, B. (2010). Engineering a protein-protein  
1441 interface using a computationally designed library. *Proc Natl Acad Sci U S A*,  
1442 107(45), 19296-19301. doi:10.1073/pnas.1006528107
- 1443 Henikoff, S., & Henikoff, J. G. (1992). Amino acid substitution matrices from  
1444 protein blocks. *Proc Natl Acad Sci U S A*, 89(22), 10915-10919.
- 1445 Hill, R. B., Raleigh, D. P., Lombardi, A., & DeGrado, W. F. (2000). De novo design of  
1446 helical bundles as models for understanding protein folding and function.  
1447 *Acc Chem Res*, 33(11), 745-754.
- 1448 Hu, X., Wang, H., Ke, H., & Kuhlman, B. (2007). High-resolution design of a protein  
1449 loop. *Proc Natl Acad Sci U S A*, 104(45), 17668-17673.  
1450 doi:10.1073/pnas.0707977104
- 1451 Jiang, L., Althoff, E. A., Clemente, F. R., Doyle, L., Rothlisberger, D., Zanghellini, A., .  
1452 . . Baker, D. (2008). De novo computational design of retro-aldol enzymes.  
1453 *Science*, 319(5868), 1387-1391. doi:10.1126/science.1152692
- 1454 Joh, N. H., Wang, T., Bhate, M. P., Acharya, R., Wu, Y., Grabe, M., . . . DeGrado, W. F.  
1455 (2014). De novo design of a transmembrane Zn(2)(+)-transporting four-  
1456 helix bundle. *Science*, 346(6216), 1520-1524.  
1457 doi:10.1126/science.1261172
- 1458 Jones, D. T. (1999). Protein secondary structure prediction based on position-  
1459 specific scoring matrices. *J Mol Biol*, 292(2), 195-202.  
1460 doi:10.1006/jmbi.1999.3091
- 1461 Kim, D. E., Blum, B., Bradley, P., & Baker, D. (2009). Sampling bottlenecks in de  
1462 novo protein structure prediction. *J Mol Biol*, 393(1), 249-260.  
1463 doi:10.1016/j.jmb.2009.07.063
- 1464 Koga, N., Tatsumi-Koga, R., Liu, G., Xiao, R., Acton, T. B., Montelione, G. T., & Baker,  
1465 D. (2012). Principles for designing ideal protein structures. *Nature*,  
1466 491(7423), 222-227. doi:10.1038/nature11600
- 1467 Kries, H., Blomberg, R., & Hilvert, D. (2013). De novo enzymes by computational  
1468 design. *Curr Opin Chem Biol*, 17(2), 221-228.  
1469 doi:10.1016/j.cbpa.2013.02.012
- 1470 Kuhlman, B., & Baker, D. (2000). Native protein sequences are close to optimal  
1471 for their structures. *Proc Natl Acad Sci U S A*, 97(19), 10383-10388.
- 1472 Kuhlman, B., & Baker, D. (2004). Exploring folding free energy landscapes using  
1473 computational protein design. *Curr Opin Struct Biol*, 14(1), 89-95.  
1474 doi:10.1016/j.sbi.2004.01.002
- 1475 Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D.  
1476 (2003). Design of a novel globular protein fold with atomic-level accuracy.  
1477 *Science*, 302(5649), 1364-1368. doi:10.1126/science.1089427
- 1478 Kulkarni, M. R., Islam, M. M., Numoto, N., Elahi, M., Mahib, M. R., Ito, N., & Kuroda,  
1479 Y. (2015). Structural and biophysical analysis of sero-specific immune  
1480 responses using epitope grafted Dengue ED3 mutants. *Biochim Biophys*  
1481 *Acta*, 1854(10 Pt A), 1438-1443. doi:10.1016/j.bbapap.2015.07.004
- 1482 Kvsanakul, M., Wei, A. H., Fletcher, J. I., Willis, S. N., Chen, L., Roberts, A. W., . . .  
1483 Colman, P. M. (2010). Structural basis for apoptosis inhibition by Epstein-

- 1484 Barr virus BHRF1. *PLoS Pathog*, 6(12), e1001236.  
1485 doi:10.1371/journal.ppat.1001236
- 1486 Lange, O. F., Lakomek, N. A., Fares, C., Schroder, G. F., Walter, K. F., Becker, S., . . .  
1487 de Groot, B. L. (2008). Recognition dynamics up to microseconds revealed  
1488 from an RDC-derived ubiquitin ensemble in solution. *Science*, 320(5882),  
1489 1471-1475. doi:10.1126/science.1157092
- 1490 Lartigue, A., Campanacci, V., Roussel, A., Larsson, A. M., Jones, T. A., Tegoni, M., &  
1491 Cambillau, C. (2002). X-ray structure and ligand binding study of a moth  
1492 chemosensory protein. *J Biol Chem*, 277(35), 32094-32098.  
1493 doi:10.1074/jbc.M204371200
- 1494 Marcos, E., Basanta, B., Chidyausiku, T. M., Tang, Y., Oberdorfer, G., Liu, G., . . .  
1495 Baker, D. (2017). Principles for designing proteins with cavities formed  
1496 by curved beta sheets. *Science*, 355(6321), 201-206.  
1497 doi:10.1126/science.aah7389
- 1498 McLellan, J. S., Chen, M., Chang, J. S., Yang, Y., Kim, A., Graham, B. S., & Kwong, P. D.  
1499 (2010). Structure of a major antigenic site on the respiratory syncytial  
1500 virus fusion glycoprotein in complex with neutralizing antibody 101F. *J*  
1501 *Virol*, 84(23), 12236-12244. doi:10.1128/JVI.01579-10
- 1502 McLellan, J. S., Chen, M., Kim, A., Yang, Y., Graham, B. S., & Kwong, P. D. (2010).  
1503 Structural basis of respiratory syncytial virus neutralization by  
1504 motavizumab. *Nat Struct Mol Biol*, 17(2), 248-250.  
1505 doi:10.1038/nsmb.1723
- 1506 Murphy, G. S., Mills, J. L., Miley, M. J., Machius, M., Szyperski, T., & Kuhlman, B.  
1507 (2012). Increasing sequence diversity with flexible backbone protein  
1508 design: the complete redesign of a protein hydrophobic core. *Structure*,  
1509 20(6), 1086-1096. doi:10.1016/j.str.2012.03.026
- 1510 Procko, E., Berguig, G. Y., Shen, B. W., Song, Y., Frayo, S., Convertine, A. J., . . .  
1511 Baker, D. (2014). A computationally designed inhibitor of an Epstein-Barr  
1512 viral Bcl-2 protein induces apoptosis in infected cells. *Cell*, 157(7), 1644-  
1513 1656. doi:10.1016/j.cell.2014.04.034
- 1514 Richter, F., Leaver-Fay, A., Khare, S. D., Bjelic, S., & Baker, D. (2011). De novo  
1515 enzyme design using Rosetta3. *PLoS One*, 6(5), e19230.  
1516 doi:10.1371/journal.pone.0019230
- 1517 Rohl, C. A., & Baker, D. (2002). De novo determination of protein backbone  
1518 structure from residual dipolar couplings using Rosetta. *J Am Chem Soc*,  
1519 124(11), 2723-2729.
- 1520 Rohl, C. A., Strauss, C. E., Misura, K. M., & Baker, D. (2004). Protein structure  
1521 prediction using Rosetta. *Methods Enzymol*, 383, 66-93.  
1522 doi:10.1016/S0076-6879(04)83004-0
- 1523 Rose, P. W., Prlic, A., Altunkaya, A., Bi, C., Bradley, A. R., Christie, C. H., . . . Burley,  
1524 S. K. (2017). The RCSB protein data bank: integrative view of protein,  
1525 gene and 3D structural information. *Nucleic Acids Res*, 45(D1), D271-  
1526 D281. doi:10.1093/nar/gkw1000
- 1527 Schreiber, G., & Fleishman, S. J. (2013). Computational design of protein-protein  
1528 interactions. *Curr Opin Struct Biol*, 23(6), 903-910.  
1529 doi:10.1016/j.sbi.2013.08.003
- 1530 Silva, D. A., Correia, B. E., & Procko, E. (2016). Motif-Driven Design of Protein-  
1531 Protein Interfaces. *Methods Mol Biol*, 1414, 285-304. doi:10.1007/978-1-  
1532 4939-3569-7\_17

- 1533 Simons, K. T., Bonneau, R., Ruczinski, I., & Baker, D. (1999). Ab initio protein  
1534 structure prediction of CASP III targets using ROSETTA. *Proteins, Suppl 3*,  
1535 171-176.
- 1536 Simons, K. T., Ruczinski, I., Kooperberg, C., Fox, B. A., Bystroff, C., & Baker, D.  
1537 (1999). Improved recognition of native-like protein structures using a  
1538 combination of sequence-dependent and sequence-independent features  
1539 of proteins. *Proteins*, 34(1), 82-95.
- 1540 Soares, T. A., Boschek, C. B., Apiyo, D., Baird, C., & Straatsma, T. P. (2010).  
1541 Molecular basis of the structural stability of a Top7-based scaffold at  
1542 extreme pH and temperature conditions. *Journal of Molecular Graphics &  
1543 Modelling*, 28(8), 755-765. doi:10.1016/j.jmngm.2010.01.013
- 1544 Stein, A., & Kortemme, T. (2013). Improvements to robotics-inspired  
1545 conformational sampling in rosetta. *PLoS One*, 8(5), e63090.  
1546 doi:10.1371/journal.pone.0063090
- 1547 Street, A. G., & Mayo, S. L. (1999). Computational protein design. *Structure*, 7(5),  
1548 R105-109.
- 1549 Tokuriki, N., Stricher, F., Serrano, L., & Tawfik, D. S. (2008). How protein stability  
1550 and new functions trade off. *PLoS Comput Biol*, 4(2), e1000002.  
1551 doi:10.1371/journal.pcbi.1000002
- 1552 Tyka, M. D., Keedy, D. A., Andre, I., Dimaio, F., Song, Y., Richardson, D. C., . . . Baker,  
1553 D. (2011). Alternate states of proteins revealed by detailed energy  
1554 landscape mapping. *J Mol Biol*, 405(2), 607-618.  
1555 doi:10.1016/j.jmb.2010.11.008
- 1556 Viana, I. F. T., Soares, T. A., Lima, L. F. O., Marques, E. T. A., Krieger, M. A., Dhalia,  
1557 R., & Lins, R. D. (2013). De novo design of immunoreactive conformation-  
1558 specific HIV-1 epitopes based on Top7 scaffold. *Rsc Advances*, 3(29),  
1559 11790-11800. doi:10.1039/c3ra41562g
- 1560 Vreven, T., Moal, I. H., Vangone, A., Pierce, B. G., Kastiris, P. L., Torchala, M., . . .  
1561 Weng, Z. (2015). Updates to the Integrated Protein-Protein Interaction  
1562 Benchmarks: Docking Benchmark Version 5 and Affinity Benchmark  
1563 Version 2. *J Mol Biol*, 427(19), 3031-3041. doi:10.1016/j.jmb.2015.07.016
- 1564 Wang, C., Bradley, P., & Baker, D. (2007). Protein-protein docking with backbone  
1565 flexibility. *J Mol Biol*, 373(2), 503-519. doi:10.1016/j.jmb.2007.07.050
- 1566 Yu, F., Cangelosi, V. M., Zastrow, M. L., Tegoni, M., Plegaria, J. S., Tebo, A. G., . . .  
1567 Pecoraro, V. L. (2014). Protein design: toward functional metalloenzymes.  
1568 *Chem Rev*, 114(7), 3495-3578. doi:10.1021/cr400458x
- 1569 Zhou, J., & Grigoryan, G. (2015). Rapid search for tertiary fragments reveals  
1570 protein sequence-structure relationships. *Protein Sci*, 24(4), 508-524.  
1571 doi:10.1002/pro.2610  
1572